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 Introduction
HAART AND CHALLENGES OF HAART
Over the last 5 years, there has been a rapid change in treatment strategies
for HIV infection. With the advent of newer antiretrovirals, treatment has
moved from mono-therapy and bi-therapy to triple drug therapy or Highly
Active Antiretroviral Therapy (HAART). Treatment with a cocktail of three
or more antiretroviral medications is now standard treatment protocol.
One of the foremost concerns of ARV programs is the ability of people liv-
ing with HIV/AIDS (PLHA) to maintain near perfect adherence over the
long term. In order to achieve the goal of antiretroviral therapy (ART), unde-
tectable levels of the virus in the blood, patients are required to maintain
more than 90–95% adherence.
Adherence is defined as a patient’s ability to follow a treatment plan, take
medications at prescribed times and frequencies, and follow restrictions re-
garding food and other medications. Both patients and health care providers
face significant challenges with respect to adherence to ART. Once initiated,
HAART is a life-long treatment that consists of multiple medications to be
taken two to three times a day with varying dietary instructions. These medi-
cations also have side effects, some of which may be temporary while others
may be more permanent requiring a change of treatment. Inadequate adher-
ence to treatment is associated with detectable viral loads, declining CD4
counts, disease progression, episodes of opportunistic infections and poorer
health outcomes.
ARV programs are being initiated in several developing countries. The
Mombasa ART project was initiated in 2003 and was designed to serve as a
learning site for other programs starting up ART service delivery in public
health facilities in Kenya as well as other countries.
This Adherence Training Manual was developed using best practices from
the New York State Medical Services, experiences from the Whitman
Walkman Clinic in Washington DC and the INOVA Juniper program in
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Virginia, training programs from the University of Florida and the WHO
VCT Counseling Manual for Asia. The manual has been developed in close
collaboration with implementing partners keeping in mind the field reality
and cultural environment of Mombasa, a coastal province in Kenya.
The Adherence Training Manual has been designed for health workers in-
cluding physicians, clinical officers and adherence nurse counselors in ARV
programs. The manual consists of four modules to be conducted over four
sessions of approximately 2 hours each. These sessions can be conducted as
a part of a comprehensive ART training program. The manual is designed
for health workers and adherence counselors who have received some train-
ing on ARV medications. In Mombasa, adherence training was introduced
on Day Two of a 5-day comprehensive ART training with a module covered
each day on days 2, 3, 4 and 5.
Module 1 provides a background on adherence to ART and is relevant for all
health workers involved in ART service delivery. Modules 2, 3 and 4 pro-
vide detailed adherence management of a patient on ART designed for ad-
herence nurse counselors. Physicians would benefit from attending the ses-
sion on Module 2. The objective for each session is given at the beginning.
The methodology, the materials required, the expected duration and the hand-
outs are given in the margin at the beginning of each exercise. Handouts for
the training use actual patient literacy materials (FHI/IMPACT 2003), coun-
seling checklists, pill charts and medication demonstration charts being used
in the Mombasa ART program.
CONDUCTING AN EFFECTIVE TRAINING PROGRAM
The ideal number of participants would be 15–20. Ideally a team of two
trainers should conduct the program. A certain amount of advance prepara-
tion is required. Trainers need to prepare by going through the additional
reading material and planning the sessions. It may be useful to have two of
the participants sum up the lessons from the previous session (previous day)
at the beginning of each day. Encouraging interactive sessions with discus-
sion will make the program more effective.
The manual uses different techniques in this module: brainstorming, small
group discussion, Power Point presentation, case studies and role-play.
Brainstorming, small group discussions and interactive sessions provide an
opportunity for a large number of participants to share their views. Power
Point presentations are useful in providing participants with the theory and
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background on the topics being discussed. Case studies help participants
discuss and understand the issues in a practical way. Role-play provides
practical training in developing adherence-counseling skills.
The manual was tested and used to train health workers and adherence nurse
counselors at Coast Province General Hospital and staff at the scale-up sites:
Port Reitz District Hospital, BOMU clinic and Magongo health centre. The
manual has also been adapted by NASCOP, Kenya.
This manual is one of the first adherence counseling training tools devel-
oped in Africa. As the ART program grows and patients have been on ART
for a longer period, new patient management issues and challenges regard-
ing adherence to treatment in the long-term will emerge. The manual will
undergo revision and updating. We look forward to learning about your ex-
periences and feedback on this training manual. Your suggestions and feed-
back will be extremely useful in improving and updating the manual.
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To provide trainees with a basic understanding of the challenges of HAART
and adherence to antiretroviral therapy
ACTIVITIES
1. Brainstorming: Discussion on adherence and challenges of
HAART. 30 min.
2. Presentation: Goals of therapy, levels of adherence required,
consequences of non-adherence, methods to monitor adherence
and strategies and tools to enhance adherence. 45 min.
3. Group activity: Discuss strategies to promote adherence. 30 min.
4. Review. 15 min.
Total 2 h
HANDOUTS
• Additional reading material on Module 1: ‘Adherence to Antiretroviral
Therapy’
• Power point presentation for Session 1
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This activity is designed to prepare trainees to understand the challenges of
adherence to HAART therapy. Most trainees will have already participated
in the general training on HIV/AIDS and antiretroviral therapy in the hospital.
The trainer will build on earlier knowledge and lead the trainees through an
initial brainstorming exercise, where information about HAART and
adherence is discussed using lead questions. The trainer will draw on
experiences with adherence to TB treatment and treatment of other chronic
diseases in the hospital. Discussion will include challenges of HAART and
factors that influence adherence. It will be based on the reading material
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The presentation will discuss the theory and more technical issues around
adherence: the goals of therapy, levels of adherence required, consequences
of non-adherence and methods to monitor adherence. The presentation will
cover issues presented in the additional reading material so that trainees recall











At the end of this session the participants
should have a basic understanding of:
Ø Challenges of adherence to HAART
Ø How adherence can be monitored
Ø How adherence can be enhanced
Enhancing Adherence to
HAART
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Challenges of adherence to
HAART
Ø Does not cure HIV infection
Ø To be taken regularly life long
Ø High pill burden
Ø Specific dietary and fluid instructions
Ø Side effects: short and long term
Adherence vs. Compliance
Adherence: the act or quality of sticking to something,
steady devotion; the act of adhering
Ø Acceptance of an active role in ones own
health care
Compliance: the act of conforming, yielding or acquiescing
Ø Lack of sharing in the decision made between
provider and client
How much adherence is required
for successful therapy?
Ø Goal of HAART = maximal and durable viral
suppression (undetectable levels)
Ø Successful HIV therapy requires adherence > 95%
Ø Failure rates increase sharply as adherence
decreases
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Consequences of poor adherence
Ø Incomplete viral suppression
Ø Continued destruction of the
immune system  CD4 cell counts
Ø Disease progression
Ø Emergence of resistant viral strains
Ø Limited future treatment options
Ø Higher costs to the individual and ARV program
Adherence to ART and Virological
failure rates (Patterson et al 2000)
Adherence and virological failure rates
Forms of non-adherence
Ø Missing one dose of a given drug
Ø Missing multiple doses of one or more prescribed
medications
Ø Missing whole days of treatment
Ø Not observing the intervals between doses
Ø Not observing the dietary instructions
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How common is non-adherence?
Ø More than 10% of patients report missing
one or more doses on any given day
Ø More than 33% report missing doses in past
24 weeks
Ø Providers cannot easily accurately guess

















Ø  Self reports
Ø  Pill counts
Ø  Pharmacy records
Ø  Biological markers
Ø  Electronic devices
Ø Measuring drug levels
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Accuracy of self-report can be
maximized by:
Ø Approaching the client in a matter of fact
and non-judgmental way!
Ø Asking about the most recent days
Ø Asking about missed doses
Ø Using prompts to help recall
Self Report
Ø Various periods of recall - 1, 3, 4, 7, 30
days
Ø Self-report agrees well with actual
medication intake and viral load
Ø Tends to overestimate
Ø Easiest to do in a clinic setting
Self Report
Pill Counts
Ø Providers count remaining pills during clinic visit
Ø Problems
Ø Patients can dump pills prior to visit
Ø Promotes a sense of distrust between patient
and provider
Ø Unannounced pill counts
Ø Done at home
Ø Can be more reliable
Ø Feasibility?
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Pharmacists keep record of medications dispensed
to patients
Can inform the doctor about lapses in patients
refilling prescriptions
Ø Problems:
Ø This is not a measure of ingestion of medications




Ø Decreasing viral load implies good adherence
Ø In some patients viral load may remain high
even with good adherence
Ø Viral resistance
Ø Treatment failure
Ø Poor absorption of drug
Others
Ø Electronic devices  MEMS
Ø Measures opening of bottles
Ø Allows for multiple measures
Ø Correlates well with viral load outcomes
Ø Expensive
Ø Training needed
Ø Measuring drug levels
Ø Expensive
Ø Drug levels in blood have short circulating times
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Ø HIV disease, CD4 counts
Ø Medications and side effects
Ø Attitudes
Ø  Positive belief and perceptions
Ø  Self efficacy and commitment
Ø Practices and support systems
Ø Disclosure, buddies, family support
Ø Identifying and addressing barriers
Ø Integrating treatment regimen into patients daily routine
Ø Encourage family involvement






Ø Buddy system (peer, friend, family)
Ø Modified DOT/DAART
Ø Incentives (food, transport, etc.)
Ø Electronic devices (pagers, alarms, beepers, etc.)
Adherence is a dynamic process
Ø Levels change over time
Ø Influenced by multiple factors, no factor
stands alone
Ø Requires a combination of promotion strategies
Ø Requires an integrated multidisciplinary
team effort
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Activity 3: Group Work
Discuss strategies to promote adherence. Divide into three groups. Groups
will be provided a list of strategies to discuss—write list on flip chart. Each
group will discuss the pros and cons of each of the listed strategies. The
groups will also list practical strategies for their program and patients. Each
group presents key points of discussion at the end of the session.








h. Directly Observed Therapy (DOT)
i. Incentives
Activity 4: Review
Review discussion of the day. Provide additional reading material. Ask two
volunteers to sum up the main points for the day. Allow trainees to ask
questions, seek clarifications or additional information. Encourage trainees
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Adherence to Antiretroviral Therapy
1. HIV INFECTION AND ANTIRETROVIRAL TREATMENT
Over the last five years, there has been a rapid change in treatment strategies
for HIV infection. With the availability of newer antiretrovirals, treatment
has moved from mono-therapy and bi-therapy to triple drug therapy or Highly
Active Antiretroviral Therapy (HAART). Treatment with a cocktail of three
(or more) antiretroviral medications is now standard treatment protocol.
1.1 What are the Challenges of Taking HAART?
HAART consists of three or more antiretroviral medications to be taken in
combination. In addition to antiretroviral medications, patients also have to
take medications for treatment or prevention of opportunistic infections. All
these medications can add up to 16 to 20 pills a day with multiple dosing
throughout the day, especially with protease inhibitor containing regimens.
The enormous pill burden  is a major challenge.
In addition some antiretroviral medications also require specific food and
fluid restrictions . For example, patients would need to take Crixivan or
Indinavir 1 hour before or 2 hours after meals and patients should drink at
least 1.5 litres of water or fluids daily to prevent formation of kidney stones.
Furthermore, HAART can often lead to adverse events that may be temporary
such as nausea, vomiting, diarrhea, fatigue etc., or longer lasting such as
neuropathy, lipoatrophy/lipodystrophy, metabolic dysfunction etc. Side effects
have been seen to be a major reason for patients discontinuing their
medications.
Antiretroviral medications control HIV virus replication or multiplication.
Even when the virus becomes undetectable in the blood with successful ART,
there are some sites in the body where drugs are unable to reach the virus.
These sites are called sanctuary sites. Therefore the virus cannot be
completely eradicated from the body and continues to remain hidden in these
sanctuary sites. The virus emerges when ART fails or is stopped. As the
HIV infection can
be managed as a
chronic disease,
but not cured.
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virus cannot be eradicated, antiretroviral medications have to be taken
regularly, long-term, for the rest of the patient’s life. HIV infection can
therefore be managed but not cured.
1.2 What is the Goal of HAART Therapy?
The goal of HAART is to achieve maximal and durable suppression of
virus replication . This in turn reduces the destruction of CD4 cells, reduces
immune suppression and slows disease progression. Success with HAART
can be seen in rising CD4 cell counts, undetectable viral loads and clinical
improvement in patients receiving HAART. As viral load assays are
expensive, in resource-limited settings, CD4 counts and clinical physical
examination become the main tools for monitoring treatment outcomes.
1.3 Viral Resistance
When patients take their medications irregularly or when providers prescribe
inappropriate doses or combinations of medications the virus is exposed to
inadequate (sub-inhibitory) concentrations of antiretroviral medications. This
in turn leads to ongoing viral replication and to the development of resistance
to antiretroviral medications. Resistance to antiretroviral medications accounts
for a large portion of treatment failures.
The critical problem is the issue of ‘cross-resistance’. Once the virus becomes
resistant to a particular antiretroviral medication, the virus may also exhibit
resistance to other medications of the same class that have not yet been
prescribed to that patient. This limits the choice of drugs available to replace
the failing regimen. For example, resistance to Nevirapine would mean that
the patient cannot use other NNRTI  medications such as Delavirdine
(Rescriptor) or Efavirenz (Sustiva).
The second issue with viral resistance is that resistant strains of the virus
can be transmitted. It has been seen that some patients diagnosed for the
first time with HIV, who have never taken ARVs, are already resistant to
some anti-retroviral medications. This is a major public health problem in
resource-limited situations where the choice of medications is already
restricted due to high costs and limited availability. It becomes all the more
important for patients to take their medications regularly and correctly to
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2. WHAT IS ADHERENCE?
Adherence is defined as ‘the act or quality of sticking to something—to adhere
to something’. In the context of treatment with medications, adherence means
a more collaborative process between the patient and provider. The patient
plays a more active role in his treatment and makes a commitment to follow
the prescribed regimen as best as possible.
How is it different from ‘Compliance’? The dictionary defines compliance
as ‘the act of conforming, yielding or acquiescing’ implying thereby a lack
of patient participation.
2.1 How much Adherence is required for
optimal results?
The goal of HAART (Highly Active Antiretroviral Therapy) is to suppress
viral load in the blood to undetectable levels (levels that are no longer
detectable in routine viral load assays). Adherence to treatment is critical to
obtain full benefits of HAART: maximal and durable suppression of viral
replication, reduced destruction of CD4 cells, prevention of viral resistance,
promotion of immune reconstitution and slowed disease progression.
Paterson and colleagues found that adherence greater than 95% is needed to
achieve virologic success, especially for protease inhibitor containing
regimens.
As adherence decreased, viral loads increased sharply in a dose response
effect. The study showed that 22% patients with adherence of greater than
95%, 61% of patients with adherence between 80–94.9% and 80% of patients
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with adherence levels of less than 80% demonstrated virological failure.
Virological failure was defined as detectable viral loads (Paterson et al., 2000).
What does 95% adherence translate into? For example Zerit (D4T) is taken
twice a day. A patient should take 60 pills over one month (30 days). To
achieve 95% adherence a patient must take at least 57 of his 60 tablets. Missing
four pills or doses would result in 93% adherence and missing five pills
would result in 91% adherence.
2.2 How common is Non-Adherence?
Unfortunately, non-adherence is common among individuals treated with
HAART. Several studies have shown varying levels of adherence: more than
10% of patients report missing one or more medication doses on any given
day, and more than 33% report missing doses in the past two to four weeks
(Chesney et al., 2000). Chesney estimated that the average non-adherence to
ARV therapy ranged from 50 to 70 percent among patients in the US.
Physicians and nurses cannot accurately guess whether a person will be
adherent or non-adherent.
2.3 How does Adherence to HAART compare
with Adherence to other medications?
Most information on adherence is coming from western countries. It is seen
that the rates of non-adherence to HIV therapies are comparable to those for
other chronic illnesses. In the case of chronic diseases such as hypertension
or diabetes lower levels of adherence, around 70–80%, are considered
adequate to achieve treatment goals. In the case of ART, near perfect adherence
(adherence levels greater than 95%) is required to obtain a successful treatment
outcome.
2.4 What are the forms of Non-Adherence?
Non-adherence can vary from missing one dose of a medication to missing a
single dose of all three or four medications to missing multiple doses or all
doses a day or week. Not observing instructions regarding dietary or fluid
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Fig. 1.2: Determinants of adherence
(J R Ickovics & C S Meade, AIDS Care, 2002)
2.5 What are the consequences of Non-Adherence?
As has been mentioned earlier, very high levels of adherence (near perfect
adherence) are required to achieve the full benefits of HAART. Non-adherence
can lead to inadequate suppression of viral replication, continued destruction
of CD4 cells, progressive decline in immune function and disease progression.
Non-adherence is also an important reason for the emergence of viral
resistance to one or more antiretroviral medications.
2.6 What are the factors that Influence Adherence?
Factors that influence adherence can be categorized to include: patient factors,
treatment regimen, disease characteristics, patient–provider relationship and
clinical setting (Fig. 2).
a. Patient factors
Patient factors that have been studied include: socio-demographic factors,
such as gender, ethnicity, age, employment, income, education and literacy;
and psychosocial factors, such as active drug or alcohol use, degree of social
support, social stability, depression and other psychiatric illnesses.
In general, socio-demographic factors do not seem to predict adherence
behaviour, although some studies have found that male sex, white ethnicity,
older age, higher income and higher education and literacy correlate with
better adherence. On the other hand, a number of psychosocial factors have
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and active alcohol or drug use prevent patients from adhering to treatment.
Social support helps patients adhere better (Ickovics and Meade, 2002).
A patient’s knowledge of his medication regimen and a patient’s
understanding of the relationship between non-adherence and build-up of
resistance to medication also predict better adherence. A patient’s belief and
confidence in therapy and his/her self-efficacy (confidence in oneself to be
able to adhere) also influence adherence to medication.
b. Medication factors
HAART consists of a complex regimen that can include up to 20 pills a day,
with multiple dosing throughout the day and specific food and fluid related
instructions. These are often difficult to follow for patients and contribute to
poor adherence. The higher the pill burden, the lower is the adherence. Patients
report taking ‘drug holidays’ as a result of ‘pill fatigue ’.
Antiretroviral medications often have side effects, some of which are
temporary: diarrhea, fatigue, nausea and vomiting; while others may be
permanent or longer lasting: peripheral neuropathy, physical changes in body
appearance, lipoatrophy/lipodystrophy, metabolic changes. Studies have
shown that when patients experience side-effects, they tend to stop treatment
or take it irregularly.
c. Patientprovider relationship
The patient–provider relationship plays an important role in improving
adherence to prescribed medications in chronic disease. It is believed to be a
motivating factor for adherence to HAART. Trust and confidence in providers
has been found to influence adherence positively (Altice et al., 2001).
d. Disease characteristics
Prior opportunistic infections (OI) contribute to increased adherence. Patients
who have had serious opportunistic infections may perceive their illness to
be severe and adhere better to their treatment (Singh et al., 1996).
e. Clinical setting
Although existing data is limited, aspects of the clinical setting may be
associated with improved adherence. A friendly, supportive and non-
judgmental attitude of health care providers, convenient appointment
scheduling and confidentiality contribute to better adherence.
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2.7 How Can Adherence be Assessed and Monitored?
Measuring adherence is problematic as there is no single method to assess
adherence accurately. There is no ‘Gold Standard’. Therefore, multiple
approaches are used to assess adherence. Some of the currently used measures
are client self report, electronic monitoring devices, pill counts, provider
estimation and measurement of medications in the blood stream.
a. Self-report
Patients are asked to report their own adherence in a self-report. Different
periods of recall may be used—four-day, one-week, one-month or most-recent
recall of missing a dose. Although patients often tend to overestimate their
adherence, several studies have found that the self-report correlates fairly
well with actual medication intake when a trusting patient-provider
relationship has been established. Self-report assessment can be obtained at
the time of clinic visits, through a series of questions asked in a non-
judgmental manner. Accuracy of the self-report can be maximized by (i)
approaching the patient in a matter of fact and non-judgmental way, (ii) asking
about the most recent days and missed doses, and (iii) using prompts to help
recall. The self-report is presently the easiest tool to use in a clinical setting.
b. Electronic devices
Medication Events Monitoring System (MEMS) consists of an electronic
chip embedded in the lid of the medication bottle. The chip records the opening
and closing of the bottle. A computer program downloads the information





Fig. 1.3: Left: MEM System; Right: MEMS Bottle
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The Medication Events Monitoring System records the date and time of each
opening of the cap and assumes that opening coincides with intake. Using
MEMS allows multiple measures of adherence to be recorded: opening
(intake), timing of opening, intervals between doses etc. Studies have found
adherence measured using MEMS caps to correlate fairly well with
medication intake. There are, however, some disadvantages associated with
its use: (i) MEMS can underestimate intake as patients sometimes remove
multiple doses at one time; (ii) both patients and providers require training
in its use; (iii) MEMS fails to work if patients leave the cap off or lose the
cap; (iv) it is very expensive—MEMS is often used to measure adherence
for only one of the prescribed medications; and (v) the use of MEMS also
precludes the use of pillboxes which patients often find useful.
c. Pill counts
Health care workers conduct pill counts during scheduled clinic visits. The
main disadvantage of this method is that patients can manipulate pills. Pill
dumping prior to scheduled visits leading to an overestimation of adherence.
This method also relies on patients to bring their medication at the time of
clinic visits.
Unannounced pill counts may be more accurate. However visiting patients’
homes is resource-intensive and there may be issues of confidentiality and
stigma in the community. Pill counting may also hinder the development of
a trusting relationship between the patient and provider.
d. Pharmacy refill tracking
Pharmacists play a key role in supporting patient adherence to medication.
Pharmacists educate the patient about their medication and conduct pill
counts. They also inform providers about lapses in refills or problems the
patient may be experiencing with taking medication. Pharmacy refill data
has been used as an additional indicator of adherence. Patients collecting
their medications regularly on due dates are assumed to be adhering to
treatment. An effective record keeping system is essential for pharmacy refill
data to be used. Some of the disadvantages with pharmacy refill tracking are
that: (i) it is not a measure of intake of medication, and (ii) it requires patients
to use the same pharmacy for all refills.
e. Biological markers
Since the goal of HAART therapy is to lower the plasma viral load, monitoring
viral load can be used as an indicator of effectiveness of treatment, and thereby
of medication intake. In some patients, however, viral loads may remain
high even though patients take all their medications regularly. This could be
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due to problems of non-response due to viral resistance, treatment failure or
poor absorption of the drug. Viral load monitoring is very expensive and
may not be available in resource-constrained settings.
f. Provider estimation
Studies have found this measure to be the most poorly correlated with
medication intake.
g. Therapeutic drug monitoring (TDM)
Measuring drug levels in blood is not being used to measure adherence due
to short circulating times for most antiretroviral medications as well as the
expense related to conducting therapeutic drug measurements. At the present
time TDM is limited only to research settings.
2.8 Strategies and Tools to Enhance Adherence
Several different strategies have been used to enhance adherence singly or in
combination.
a. Counseling
Counseling forms the mainstay of any treatment program. Counseling aims
to improve patient knowledge about the disease and knowledge about the
medications and side effects. Counseling helps the patient to set goals, to
develop positive beliefs and perceptions and to increase self-efficacy. In
addition to counseling, patients often need other forms of support to be able
to adhere to treatment.
Adherence tools are helpful for many patients. Several different types of
tools are in use, as listed below.
b. Pillboxes
Pillboxes are containers for storing medication with dividers for each day
and each dose within the day. This makes it easy for patients to take doses
correctly. Pillboxes with electronic reminders are also available. Some
pharmacies in the west even distribute pre-loaded pillboxes. A possible
disadvantage of the pillbox in developing country settings may be its visibility
in situations where patients need to hide medications from others due to
confidentiality reasons. Patients who are illiterate or very sick may need help
to fill the pillboxes correctly.
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Many treatment programs in developed countries use electronic devices to
enhance adherence to medications. Devices range from beepers to alarms
to watches that remind patients to take medications on time. El ctronic
pagers that are linked to the internet are used to send messages to patients.
Electronic devices need to be discreet to avoid stigma and confidentiality
related issues. These tools may not be practical in developing country settings.
MEMS can be used both to measure adherence as well as a reminder tool for
patients.
d. Telephone reminders
Telephone reminders are being tried out in some studies on adherence. There
are several limitations to its use: it is labour intensive for staff, patients must
have a telephone at all times and cost issues. Internet based confi ential
reminder services are also being used.
e. Medication diaries
These are diaries in which patients record the time and date of medication
intake, missed doses and reasons for missed doses. These can serve as useful
records of side effects or other problems patients may experience. This is a
useful tool to identify patterns of use and reasons for missing doses.
f. Buddy system
The Buddy system relies on a friend or family member to help the patient to
take medications regularly—reminding the patient to take his medication on
time, offering encouragement to keep going, helping to keep hospital
appointments, providing support etc.
Fig. 1.4: Ezy Dose Pill Box (1 week, 4 daily doses)
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Pill charts are used to visually display pills (colour and shape), names and
dosage for each medication and are used by the nurse or health provider during
counseling. This is a very useful tool for patients with literacy problems.
All the strategies, a to g, outlined above serve as ‘enablers’ for patients,
helping patients organize their treatment taking.
h. Directly Observed Therapy (DOT)
DOT is an intensive program in which patients take their medication under
the supervision of adherence staff. In TB DOTS programs health workers
observe the intake of all medication doses for the entire treatment period of
6–9 months. TB DOTS is more regimented and provides a tighter monitoring
of medication intake. In the case of ART, it is not practical to observe all
doses as most HAART regimens have multiple doses and treatment is life-
long. Therefore, only some doses are observed for a fixed period of time (a
few months). This is called modified DOT or directly administered
antiretroviral therapy (DAART). Modified DOT can be done at health
centres, in community-based organizations or even at a patient’s home. In
the management of HIV infection, a modified DOT strategy, through frequent
patient–provider contact, is used as a behavioural intervention that helps
patients (i) to develop an understanding of the treatment; (ii) to develop good
treatment taking behaviour; (iii) to receive support during the first few weeks
of antiretroviral therapy when patients have short term side-effects; and (iv)
to develop a trusting relationship with providers.
i. Incentives
Several programs in the US are using incentives such as telephone cards,
transport and food coupons, shopping coupons, movie tickets, tickets to sports
events etc. to increase effectiveness of ART intake.
Adherence is a dynamic behaviour
 Adherence levels change over time.
 Adherence is determined by a matrix of inter-related
factors that shift over time. No factor stands alone.
 Adherence requires an integrated, multidisciplinary
approach: physicians, nurses, counselors and pharmacists.
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To provide trainees with an understanding of
§ Initial assessment of the patient
§ Barriers to adherence
§ Patient preparation for starting antiretroviral therapy.
ACTIVITIES
1. Brainstorming: Discuss barriers to adherence. 30 min.
2. Presentation and discussion on patient assessment,
barriers and patient preparation for antiretroviral therapy. 60 min.
3. Review. 15 min.
Total 1 hr 45 min.
HANDOUTS
§ Additional reading material on Module 2: Patient Preparation for
Adherence
§ Power Point presentation for Session 2
§ Barriers and ways to address them
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This activity is designed to improve trainees’ knowledge about patient
preparation prior to initiating antiretroviral therapy. The trainer will build on
the information provided in Module 1. The trainer will lead the participants
through a brainstorming exercise to identify barriers to adherence and the
role of the different health providers. The trainer will ask participants to list
possible barriers for PLHA and ways to address them. The trainer will use
lead questions that are based on the Additional Reading Material provided
in this Module enabling trainees to recall the issues discussed when going
through the reading material.
In case the group is too large, this activity may be done in two groups. Each
group will present their findings.








List of Barriers to Adherence and Ways to Address Them
Handout for Group Discussion
1. Communication difficulties (language, cultural differences, patient attitudes regarding treatment
efficacy, lack of comprehension about treatment plan or regimen)
i. Discuss in an open and non-judgmental way
ii. Provide patients with scientific basis for treatment
iii. Repeat and paraphrase
iv. Use counselors who speak the same language and understand the
cultural context of the patient
2. Literacy levels
i. Verbal repetition of adherence message, treatment plan and regimen
ii. Use patient literacy materials
iii. Use dummy pills for demonstration
iv. Review information with patient
3. Inadequate knowledge or awareness about HIV disease
i. Provide patients with scientific information about HIV disease
ii. Review information with patient
iii. Use examples
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4. Inadequate understanding about effectiveness of medications
Inform patient and bring change in attitudes and understanding of effectiveness of medications
5. Lack of social support
i. Establish contact with PLHA support groups
ii. Link with community health workers and home-based care services
iii. Link with charitable institutions, Faith Based Organisations
6. Discomfort with disclosure of HIV status
i. Counseling patient to support disclosure
ii. Identify other support persons like friends or peers if patient unable to disclose
to the family
7. Difficult life conditions (lack of income, housing and food; lack of support for childcare)
i. Establish contact with PLHA support groups
ii. Link with community health workers and home-based care services
iii. Link with charitable institutions, church programs
8. Alcohol and drug use
i. Counseling—emphasize link between alcohol, ARV medications and liver damage
ii. Family support
iii. Peer group support programs, church programs
iv. Medical consultation—de-addiction programs
9. Depression and other psychiatric problems
Refer to physician for treatment
10.Negative or judgmental attitude of providers
Training of providers
11. System barriers (drug stock-out, shortage of staff, health facility closed)
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Activity 2: Presentation and Discussion
The presentation will focus on risk assessment and patient preparation to
start treatment.
The presentation will cover issues presented in this module so that trainees
recall the issues presented when reading the material.
Discussion can be interwoven with the presentation to form an interactiv
session. The discussion will focus on patient factors: knowledge of HIV
disease, perceptions about disease severity, commitment to take treatment,
self-efficacy, barriers etc. Some of these issues have been covered in Module
1; the trainer will build on earlier knowledge during this session. Participants
will be encouraged to discuss the issue with relevance to local conditions
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At the end of this session participants
should have a basic understanding of
Ø Initial assessment of the patient
Ø Barriers to adherence
Ø Preparation of the patient
Why assess the patient?
HAART is a complex treatment to be taken life-long
We need to know:
Ø Does the patient understand his disease?
Ø Is the patient ready to make a commitment
to a life-long treatment?
Ø What are some of the problems the patient may have
that will prevent him/her taking medications regularly?
Initial assessment of a patient (1)
§ Learning about the patients health status
Detailed medical history includes:
Ø General physical health
Ø Past illnesses  OIs, hospitalizations
Ø Mental health  depression, dementia
Ø Substance abuse  alcohol, drugs
Ø Other medications  prior use of ART,
experience with adherence
32 • MODULE 2: Patient Preparation for Adherence










Initial assessment of a patient (2)
Initial assessment of a patient (3)
Initial assessment of a patient (4)
 Learning about the patients beliefs and
attitudes about HIV infection and treatment.
What does the patient think about:
Ø Effectiveness of HAART
Ø Commitment to treatment
Ø Perceptions about seriousness of his/her illness
Ø Continuing preventive and protective behaviour
 Learning about the sources of social support
Ø Lives with family/lives alone
Ø Support from family and friends
Ø Support from outside the family  NGOs,
church, workplace etc.
Ø Disclosure of his/her HIV status
 Learning about socio-economic status
Ø Housing
Ø Employment and income
Ø Dependants
Ø Migrant status and home district
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Barriers to adherence (1)
Barriers to adherence (2)
Ø Communication difficulties
Ø Literacy levels
Ø Inadequate knowledge or awareness of
HIV disease
Ø Inadequate understanding of treatment
regimen
Ø Discomfort with disclosure of HIV status
Ø Patient attitudes and beliefs in treatment
efficacy
Ø Depression and other psychiatric problems
Ø Alcohol and/or active drug use
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Barriers to adherence (3)
Patient preparation
Patient preparation (1)
Ø Difficult life conditions
Ø Unstable living conditions
Ø Negative or judgmental attitude of health
providers
Ø System barriers
Ø Requires 2-3 (even 4) sessions with the patient
prior to starting HAART
Ø Sets the ground for better adherence long-term
Ø Ongoing process with a two-way exchange
between patient and provider
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Ø Establishing trust between patient and provider
Ø Introduction to the treatment and adherence
program
Ø Discussion about:
Ø Patients present health status
Ø Past experience with ART and adherence
Ø Expected changes in physical well being and
biological markers with ART
Ø Importance of adherence
Ø Discussion about:
Ø Patients living conditions
Ø Patients daily routine
Ø Understanding of patients beliefs and attitudes 
HIV disease, ART, preventive behaviour
Ø Identification of potential barriers & ways to
address them
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Ø Making a treatment plan
Ø Treatment regimen
Ø Follow-up plan
Ø Integrating treatment into patients daily
routine
Ø Discussion about proposed adherence strategy
Assessment of patient readiness
Before starting ART
Ø Patient should demonstrate an understanding of his/
her disease and health status
Ø Patient should demonstrate an understanding of his/
her treatment regimen and follow-up plan
Ø Patient should appear to make a commitment toward
adhering to treatment
Ø Potential barriers should have been identified and
addressed to the best possible extent
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Activity 3: Review: Q & A
Review discussion of the day. Ask two volunteers to sum up the main points
for the day. Allow trainees to ask questions, seek clarifications or additional
information. Give out additional reading material. Encourage trainees to read
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HAART is a complex treatment with multiple medications that once started
need to be taken long-term. It is extremely important to take time to assess
and prepare the patient for this treatment. Setting the ground for adherence
to treatment begins before antiretroviral therapy is started. Treatment programs
need to have a consistent approach to patient readiness assessment.
The initial assessment of patients forms the basis for setting up a successful
treatment adherence plan. During the assessment the counselor should aim
to learn as much as possible about the patient’s health and psychosocial
background.
Initial assessment should include the following points:
§ Learning about the patient’s health through a detailed medical history.
§ Learning about the prior use of antiretrovirals  and other medications.
§ Learning about the patient’s beliefs and attitudes about HIV and
treatment.
§ Learning about the sources of social support.
§ Learning about the socio-economic situation of the patient.
§ Identifying barriers to adherence.
2. PATIENT PREPARATION FOR TREATMENT
Patient preparation is an important step that goes a long way in getting patients
to take treatment correctly as prescribed over the long term. Preparation
includes the initial assessment of the patient and can be done over three to
four visits before initiating ARV therapy.
The preparation process is important for both patients starting treatment for
the first time (treatment-naïve), as well as those who may have used anti-
retrovirals in the past (treatment-experienced). For treatment-naïve patients,
the preparation process helps patients (i) understand the challenges of taking
HAART, (ii) to think through the impact treatment will have on their lives, and
(iii) to help patients make a commitment to long-term treatment. For
treatment-experienced patients the preparation process helps (i) to re-evaluate
their commitment to taking treatment, (ii) to identify potential and actual
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The Health Belief Model of behaviour change is based on the theory that
persons usually perceive a threat to their health (in terms of severity and
susceptibility) and expect certain outcomes before they adopt new behaviours
and develop the self-efficacy to make the change. Based on this theory, the
process of behaviour change in a person is thought to have five stages:
§ Pre-contemplation: when the person is unaware or not interested in
changing behaviour,
§ Contemplation: when the client thinks about behaviour change,
§ Preparation: when a person actively decides to change,
§ Action: the person works at changing behaviour,
§ Maintenance: when a person is able to sustain behaviour change for more
than 6 months.
The preparation process works on these principles. It gives patients time to
understand their disease and its severity and to understand the need to take
medications to achieve health benefits. It helps the patient to make a
commitment to take treatment regularly and correctly to achieve desired health
outcomes. The preparation process helps to empower patients prior to starting
treatment.
Preparation of the patient includes the following.
2.1 Establishing Trust Between Patient and Provider
The first step in preparing the patient is to establish trust. This is an ongoing
process that is strengthened over time. An assurance of confidentiality, a
non-judgmental attitude, mutual respect and clear communication of
information contributes greatly to developing a trusting relationship between
provider and patient.
2.2 Introduction to the Treatment and Adherence
Program
A discussion about the ARV program, health facility, medication availability,
laboratory facilities and support services helps to familiarize the patient with
the treatment program. An introduction to the staff providing services and
familiarizing the patient with the clinic layout is an important step in putting
the patient at ease.
It is important to emphasize that disease progress can be delayed with
treatment if taken regularly. Patients should be given a positive message.
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Patients who have adhered well to their treatment are in good health more
than decade after they started treatment.
2.3 Assessing the patients health status
Learn about the patient’s health through a detailed medical history. This
includes an assessment of general health status, past illnesses and
hospitalizations and mental health. Patients who have experienced serious
infections or hospitalizations may perceive their illness as serious and adhere
better to treatment. Patients with severe mental illness may need help with
taking medications regularly.
a. Overall health
A discussion on the overall physical and mental health status, ability to be in
control of his/her life, and ability to conduct routine daily activities sets the
stage for the discussion on the importance of taking medications regularly. A
detailed medical history forms the basis for understanding some of the barriers
to adherence.
b. Disease stage
A discussion on past opportunistic infections the patients may have had and
what it implies in terms of disease progression helps patients understand the
severity of their illness and the need to take medications correctly. It is
important to emphasize that progress of the disease can be delayed with
treatment if taken regularly and correctly.
The modified WHO staging for HIV infection and disease uses clinical and
laboratory staging to determine disease stage (Tables 1 and 2). The modified
WHO staging has been used for predicting progress to stage IV disease. The
predicted time for disease progression from stage III to IV is approximately
2 years and the estimated survival for patients in stage III and IV is 3.7 years
and 1.7 years (Table 3). Even in cases of patients with advanced disease,
care must be taken not to discourage them with predications of life-
expectancy.
When started in time, HAART delays disease progress and prevents death.
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Information on WHO disease stage and estimated survival is given in the
following tables.
Table 2.1: WHO Clinical Staging for Disease
Stage 1 Asymptomatic, peripheral general lymphadenopathy, acute HIV
Stage 2 Loss of weight < 10%, minor mucocutaneous lesions, zoster within
last 5 years and recurrent upper respiratory illnesses
Stage 3 Loss of weight > 10%, chronic diarrhea > 1 month, thrush, oral
hairy leukoplakia, TB within past 1 year, severe bacterial infections
Stage 4 Wasting syndrome, any ADI (AIDS Defining Illness)
WHO Wkly Epid Rec 1990 65:221
Table 2.2: Modified WHO Staging for HIV Infection and
Disease
CD 4 Lymphocytes WHO 1 WHO 2 WHO 3 WHO 4
> 500 > 2000 I I II IV
200–500 1000–2000 II II III IV
< 200 < 1000 III III IV IV
Montaner J et al. AIDS 1992 6:719
Table 2.3: Evaluation of Modified WHO Staging System
for HIV Infection and Disease
Estimated time for disease progression to stage IV
Stage I to IV 9.5 years
Stage II to IV 6.5 years
Stage III to IV 2.0 years
Estimated survival
Stage I 11.2 years
Stage II 8.2 years
Stage III 3.7 years
Stage IV 1.7 years
Schecter M T et al. JAIDS 1995 8:474
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It is important to discuss the CD4 cell count with patients. The discussion
should cover the following points:
• CD4 cells counts are a measure of the patient’s immune status,
• HIV attacks CD4 lymphocytes,
• lower CD4 counts signify advanced HIV disease,
• CD4 cell counts increase with treatment.
The patient should be explained how lower CD4 counts are associated with
an increase in the number of episodes of opportunistic infections (OIs) and
continued disease progression; and how higher CD4 counts indicate a lower
risk of OIs and improved health status. Patients should know their CD4
cell count and monitor how it changes with treatment. Patients who have
knowledge about their disease tend to exhibit higher levels of adherence to
treatment.
CD4+ T Cell counts
Ø CD4 cells are lymphocytes with CD4 receptors that play a critical role
in the function of the immune system to fight off infections. They are
also called T cells.
Ø The virus is particularly attracted to CD4 cells and destroys them,
thus lowering the body’s immunity against infections. Measuring the
number of CD4 cells in the body is one method of determining how
well the immune system is functioning. A person with a normally
functioning immune system has between 600-1200 CD4 cells.
Ø When CD4 counts fall to below 200, people who have HIV infection
and are not on preventive medications may develop a host of
opportunistic infections (PCP – AIDS related pneumonia, recurrent
herpes zoster, fungal infections, cancerous skin lesions etc.).
Ø Treatment with antiretroviral medications reduces the number of virus
in the body and thereby decreases the destruction of CD4 cells. With
successful treatment, CD4 cell counts increase, restoring immune
function and patients experience fewer or no opportunistic infections.
CD4 cell counts can rise anywhere from 50–150 cells or more with
successful treatment. This rise may take several months as it depends
on how severely the patient’s immune system was affected at start of
treatment.
Ø Patients with CD4 cell counts at or below 200 cells/cm3 are eligible to
receive antiretroviral medications in this program.
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d. Viral load (VL)
It is desirable to discuss the viral load with patients even when it may not yet
be available for routine monitoring. The discussion should cover the
following:
• viral load measures the amount of HIV in the blood,
• higher viral load levels signify increased risk of transmitting infection,
• treatment with ART results in viral load reduction,
• patients start to feel better when viral load decreases.
The patient should understand how viral load measurements change in
response to effective treatment.
Viral Load
Ø Viral load tests measure the amount of HIV virus in the bloodstream.
If the viral count is high, it means that the virus is in a period of greater
activity, replicating (producing copies of itself ) and further infecting
new cells.
Ø Viral load tests when available (they are very expensive and require
advanced laboratory facilities) are used to determine the need for
therapy and assess prognosis.
Ø Successful treatment with highly active antiretroviral therapy (3 drug
cocktail) should result in a reduction in viral load. Viral load should /
can go down ten-fold in the first 8 weeks and then further to
undetectable levels in 16–20 weeks.
Ø The rate of viral load decline is affected by the baseline CD4 cell count,
initial viral load, potency of the regimen, adherence to treatment, prior
antiretroviral medication use and the presence of OIs.
Ø Viral loads tend to be the highest during initial acute HIV infection
(acute HIV syndrome) and in advanced disease.
2.4 What Patients Can Expect to See with Treatment
A discussion on the changes in the CD4 counts and viral load measurements
with successful treatment should be included. Emphasize the connection
between regular and correct medication taking with improving immune
function, improvements in general physical conditions, weight gain, fewer
opportunistic infections and slowed progression to AIDS.
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2.5 The Importance of Adherence
Preparatory counseling should emphasize the importance of adherence to
treatment in order to achieve viral load suppression and treatment success.
Patients should understand the link between regular intake of medication or
higher adherence with a decrease in viral load, increase in CD4 cell counts
and treatment success. Consequences of non-adherence such as ongoing
increase in viral load, decrease in CD4 cells and immune function and disease
progress should be discussed. The counselor should emphasize the need for
taking every dose every day and correctly with respect to time intervals and
dietary instructions. A twice-daily dose is to be taken 12 hours apart, a thrice-
daily dose to be taken 8 hours apart etc.
2.6 Prior Use of Antiretrovirals
A discussion on prior use of antiretrovirals and experience with adherence
to treatment is important. Patients with prior adherence problems or irregular
use of antiretroviral medications would need added support and counseling.
Information on other medications that the patient may be taking is required
to assess drug interactions and side effects.
2.7 Patients Beliefs and Attitudes
Learn about the patient’s beliefs and attitudes about HIV and treatment.
Positive attitudes and beliefs support adherence. Patients who believe that
treatment is beneficial, are able to make a commitment to long-term treatment
and are confident that they will be able to take medications correctly and
regularly, tend to adhere better to treatment.
2.8 Social Support and Socio-Economic Situation
The initial assessment and preparation should include a discussion on the
sources of social support for the patient. Does the patient live alone or with
his family? Has s/he disclosed her/his HIV status to the family? Does the
patient have a friend or family member that s/he trusts and expects support
from? The discussion should include sources of support from outside the
family such as NGOs, PLHA support groups, religious or faith based
organizations or workplace programs etc.
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Learn about the socio-economic situation of the patient: housing,
employment and income, number of dependent family members, migrant
status, living conditions—factors that may influence regular and correct intake
of medications.
It is important to discuss the patient’s daily routine (employment, work timing,
eating and sleeping pattern), HIV confidentiality issues at place of work and
at home, medication storage and travel plans so as to identify areas where
patients may have problems and need support. An understanding of the
patient’s daily routine and lifestyle helps to better integrate medication intake
into the daily routine. Treatment reminder cues can be identified based on
the patient’s daily routine. Treatment reminder cues include tying medication
intake to mealtime or specific routine activity such as leaving for work, notes
written to oneself and placed at strategic points in the house, medication
kept at a strategic location in the house.
2.9 Establishing a Treatment Plan
i. A discussion about the treatment regimen should cover the following
points: medication names, dosing instructions, food and fluid intake
requirements, and storage of medications. It is extremely important for
the patient to know and understand their treatment regimen to enable
them to take an active role in managing their HIV disease.
ii. A discussion about potential side effects and ways to manage them;
when to seek care and how to contact providers should be included.
Preparing the patient in advance about the side effects, that they might
expect to see, removes the surprise or fear and prevents patients from
stopping medications on their own.
iii. A discussion on the plan for routine follow-up should be included.
Counselors should establish a contact system so patients can contact
the provider in the case of need: medication side effects, illness,
psychosocial problems etc. Providers may also need to contact the patient
in case of missed appointments. Telephone numbers and addresses
should be exchanged. Patients should be encouraged to discuss travel
plans in advance so that extra medications can be issued to cover periods
away.
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2.10 Discussing the Proposed Adherence Strategy
A discussion, early in the preparation process, on the adherence promoting
strategies to be used, helps to increase acceptability and commitment. A
range of strategies have been discussed in Module 1.
Family support should be encouraged for all patients. Patient preparation
should include the adherence promotion strategy to be used for the client
(tools such as checklists, pill diaries, pill boxes; modified DOT, buddy system
etc.).
3. IDENTIFYING BARRIERS TO ADHERENCE
Identifying barriers to adherence forms an essential component of patient
assessment and patient preparation. Barriers vary from person to person and
within the same person from time to time. The treatment preparation process
should ensure that potential or actual barriers are identified. The patient and
provider can work together to address these barriers at the patient level, while
the health system can address the barriers at the service delivery level.
Barriers to adherence could include:
a. Communication problems
Communication difficulties may arise from language and cultural differences.
Communication difficulties could also arise when the patient’s attitudes and
expectations regarding HIV and treatment are different from those of the
providers. Some patients may be defensive about their lifestyle and exhibit
negative attitudes. This may be seen among marginalized or stigmatized
groups.
How to address the barrier: Discussion in an open and non-judgmental way,
paraphrasing and repeating information, providing patients with a scientific
basis for HIV treatment and related issues helps patients develop self-
confidence and positive attitudes. Understanding cultural differences and
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Fig. 2.1: Pill Diary
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Patients with low literacy levels may not completely understand their disease,
its challenges and complications. Patients may not comprehend instructions
provided.
How to address the barrier: Use verbal repetition of the adherence message,
treatment plan and regimen. A practice session with dummy pills may help
patients. Using pictorial representation of the message may be helpful.
Reviewing written information with each patient, describing technical terms
in simple language and asking patients to repeat instructions may be helpful.
Efforts should be made to avoid uncomfortable situations where the patient’s
lack of or lower levels of literacy are revealed. This encourages a sense of
trust in the provider and self-efficacy in the patient.
c. Inadequate knowledge or awareness about the disease
and effectiveness of medications
Patients who understand their HIV disease and the relationship between
treatment, adherence and successful outcomes do better than patients who
do not have such an understanding. Patients who believe in the effectiveness
of medications also do better with treatment.
How to address the barrier: Discussion in an open and non-judgmental way,
paraphrasing and repeating information, providing patients with a scientific
basis for HIV treatment and related issues will help patients develop self-
confidence. Presenting a case study or experience from other patients may
also help patients develop positive attitudes and confidence in the
effectiveness of treatment.
d. Unstable living conditions and lack of social support
Patients may be living alone, living in shared accommodation or living on
the street. Unstable living conditions pose a major barrier to proper medication
intake and storage. These patients also tend not to have family or outside
support thereby missing out on a caring atmosphere, proper nutrition and
stability in their personal lives.
How to address the barrier: Establishing contact with PLHA support groups,
if the patient is willing, may be helpful in getting some support. Linking the
patient with a home-based care program and CHWs (Community Health
Workers) may provide some psychosocial support and nursing care. Support
programs run by faith based organizations, such as food donation programs,
may provide an additional source of support.
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e. Discomfort with disclosure of HIV status
Disclosure of HIV status is an important factor influencing adherence. Fear
of rejection or discrimination may prevent PLHA from disclosing their status
to family members and friends thereby losing out on social support. Patients
may not want to take their medications in the presence of colleagues at work
or family members at home and so choose to skip that particular dose of
medication.
How to address the barrier: Counseling can help the patient to overcome
some of these fears and help with disclosure to the family or friends. Once
the patient is ready to do so, counseling for family members to facilitate
disclosure may be required. It is important that these family members are
identified by the patient. In cases where patients are not ready to disclose
their status, counselors can help patients identify a person or two outside the
family who could provide psychosocial support, for example peers, friends,
PLHA support groups.
f. Difficult life conditions
Patients who do not have housing, are unemployed, have very modest or no
financial means, may perceive the lack of income, housing and food, support
for childcare as more urgent needs than taking medications properly.
How to address the barrier: While it may not be possible for the health
worker to directly address these problems, linking patients with church
programs, PLHA support groups and the home-based care program may offer
some help. Some church programs provide food donation and PLHA groups
have income generation activities.
g. Alcohol and drug use
Patients with heavy alcohol intake or active drug use have problems in
adhering to treatment—forgetting to take medications on time or correctly.
How to address the barrier: Counseling is an important tool. Patients should
be provided scientific information on the link between alcohol, ARV drug
metabolism in the liver and resulting exacerbation of liver damage. It may
become necessary to stop or change ARV medications if liver damage occurs.
Discussion in an open and non-judgmental way is essential. Linking patients
with PLHA support groups and peer group interventions may be helpful.
Counselors would need to ask a family member to remind the patient about
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medication intake (only when the patient has disclosed his/her HIV status).
Referring patients to active de-addiction programs, where available, is useful.
h. Depression and other psychiatric problems
Patients with depression and other psychiatric illness may have difficulties
in adhering to treatment. Patients with advanced HIV disease may have HIV
disease-related conditions such as AIDS dementia, which may prevent patients
from caring for themselves and taking medications regularly and correctly.
Patients may suffer from residual confusion after an episode of meningitis or
encephalitis.
How to address the barrier: Active depression can be treated with anti-
depressants. Physicians can assess the patient and provide relevant medical
care. Treatment with ARV in itself helps to resolve some conditions. AIDS
dementia may not improve despite ART and these patients require additional
support. Enlisting support, to help patients take their medications on time,
from the family, community health workers, and PLHA support groups would
be required.
i. Negative or judgmental attitudes of providers
Patients who perceive their providers as having antipathy towards them or a
negative and discriminating attitude are understandably reluctant to adhere
to treatment and maintain a regular schedule of follow-up care.
How to address the barrier: Training of providers will help to overcome this
barrier. Regular staff meetings to discuss the follow-up of patients may help
providers to understand the issues better.
j . System barriers
Patient adherence may be influenced by health system barriers, such as: health
facility being closed, no drugs in stock, patients being turned away due to
staff being too busy etc.
These barriers need to be addressed by the management. Counselors may
help by bringing these issues to the administration’s notice.
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4. NUMBER OF PREPARATORY VISITS
For adequate patient preparation, two to three or even four preparatory visits
may be required where patients receive adherence counseling and practice
with medications. Following the final preparatory visit, the treating physician
and nurse counselor can assess patient readiness to initiate treatment. It may
be best to initiate treatment when:
§ The patient demonstrates an understanding of his/her disease
§ The patient demonstrates an understanding of the treatment regimen
§ The patient demonstrates an understanding of the link between adherence
to treatment and successful treatment outcomes (such as improved
immune status, increasing CD4 counts, decreasing viral load etc.)
§ The patient is able to make a strong commitment towards adhering to
treatment.
Although, some patients may require more than three sessions to be adequately
prepared, it may not be possible to delay initiation of therapy any longer due
to the disease already being at an advanced stage. Patients may also not be
willing to delay initiation of therapy. In such situations, additional counseling
sessions can be administered alongside initiation of therapy.
5. THE MULTIDISCIPLINARY ADHERENCE TEAM
HIV is a complex illness that has an impact on many aspects of an individual’s
health and life. Several factors influence adherence to treatment, necessitating









Family / FriendFamily / Friends
Physician
Fig. 2.2: Multidisciplinary Adherence Team
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It is useful to have the message on adherence repeated at multiple points by
the various providers involved in providing care. Enlisting support from
family members and friends, where possible, is encouraged. A participatory
approach where patients take part in making decisions regarding medications
and adherence strategy has been seen to contribute to improving adherence.
5.1 Role of the Physician
§ Leader of the case management team
§ Main person to take decisions regarding
• Initiation of ART
• Continuation of therapy
• Treatment failure or non-response
• Side effects/adverse events and appropriate response
• Change of treatment regimen
• Adherence to treatment
• Prophylaxis therapy
§ Responsible for overall health status of patient
§ Provides information on adherence.
5.2 Role of the Nurse Counselor/Nurse Case Manager
§ Adherence Counselor for individual patients working in close
collaboration with the physician.
§ Responsible for
• Adherence counseling for patients
• Adherence-related follow-up and data collection
• Adherence strategy to be used
• Liaising with different specialties involved in case management
(e.g. TB services, dermatology, home based care).
• Informing physician of problem areas: side effects, adverse events
and psychosocial problems.
5.3 Role of the Pharmacist
§ Member of the treatment and adherence team
§ Responsible for
• Dispensing of medications
• Treatment-related counseling
• Adherence counseling at time of dispensing treatment
• Checking out for side effects and adverse events
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§ To provide trainees with skills in the initial assessment of a patient
§ To provide trainees with skills in preparatory counseling for patients prior
to initiating HAART
ACTIVITIES
1. Brainstorming on adherence counseling—its nature and
purpose and on attributes of an effective counselor 30 min.
2. Presentation on the content of counseling during
first three sessions 40 min.
3. Case studies through group discussions 45/60 min.
4. Review or summary 15 min.
Total Time: 130–145 min.
HANDOUTS
§ Additional reading material on Module 3: Preparatory Adherence
Counseling
§ Checklists for the three preparatory counseling sessions
§ Effective counseling techniques handout
§ Patient literacy materials
§ Demonstration pill chart
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This activity is designed to provide trainees with adherence counseling skills
and to make them aware of the nature of the long-term relationship with the
patient.
The trainer will build on the information provided in Module 2. Participants
will break up into 2–3 groups and come back for a plenary. The trainer will
lead the participants through a brainstorming exercise to understand the nature
and purpose of adherence counseling, the attributes of an effective counselor
and effective counseling techniques. The trainers will use lead questions
that are based on the reading material provided in this module enabling
trainees to recall the issues discussed when going through the reading material.
Handout for Effective Counseling Techniques
Discuss the following techniques to make counseling more effective.
§ Active attending or listening
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The presentation will focus on the topics that need to be covered in the first
three adherence counseling sessions prior to initiating HAART and will cover
topics presented in Module 3. The session should allow for an interactive
discussion with trainees during the presentation with a special focus on the





At the end of this session participants should
have a detailed understanding of
Ø Content of the three preparatory counseling
sessions
Ø Assessment of patient readiness to start
treatment
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Setting the ground for adherence
First Counseling Session
Step 1: Introduction to the treatment and
adherence program
Ø Explain layout of clinic, laboratory, pharmacy
Ø Introduce HWs involved in care
Ø Explain overall treatment and follow-up plan:
§ 3 counseling sessions prior to starting ART
§ Monthly follow-up with physician
§ Monthly pharmacy refill & laboratory
investigations as required
Make the patient feel comfortable!
Step 2: Discuss patients health status
Ø Overall health and physical condition
Ø Disease stage and past OIs
Ø CD4 counts and viral load
Ø Expected changes in health and CD4 counts
with regular ART
Ø Importance of > 95% adherence
Ø Consequences of non-adherence
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Patients health status (contd)
Ø Past use of ARVs/Other medications
Ø Alcohol/drug use
Ø Pregnancy and family planning
Ø Protective and  preventive behaviour
During the session assess:
Ø Patients beliefs and attitudes about HIV
infection and treatment
Ø Patients mental health
Step 3: Discuss Patients Living Conditions and
Social Support
Ø Employment and income
Ø Living condition  housing,
Ø Disclosure of HIV status
Ø Social support
Ø Dependants  other HIV infected persons
Ø Migrant status and travel
Ø Daily routine
Step 4: Discuss treatment plan
Ø Treatment regimen
§ Names and doses
§ Instructions on food and fluid intake/restrictions
§ Storage of medications
§ Take all doses of all medications and do not share!
Ø Side effects  discuss briefly, do not overwhelm the
patient
Ø Follow-up plan
§ Next two counseling sessions
§ Physician check up and investigations
§ Contact information  HW and patient
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Ø DAART (Modified DOT)
Ø Treatment Buddy
Ø Family involvement
Ø Tools: Pill diary, treatment reminder cues etc.
Step 5: Discuss the proposed adherence strategy
Step 6: Identify barriers to adherence
Ø Identify potential barriers  from earlier
discussion
Ø Discuss ways to address barriers
Step 7: Fix a date for the next appointment
Continued Adherence Counseling:
Second Counseling Session
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Ø Use an approach of continuing discussion and
not an evaluation
Ø Repeat information where necessary
Ø Re-emphasize important issues
Ø Use dummy pills to repeat instructions
Counseling Session 2 (contd)
Step 1:
Review and assess patients understanding of
his/her HIV disease and health status
Step 2:
Review and assess patients understanding and
recall of treatment and follow-up plan
Counseling Session 2 (contd)
Step 3:
Provide information on side effects
Ø Expected side effects
Ø How to manage them
Ø When to seek care
Ø How to contact health worker
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Counseling Session 2 (contd)
Step 4:
Review proposed adherence strategy
Step 5:
Review barriers and how to address them
Step 6:
Fix a date for the next appointment




Review treatment regimen and follow plan in detail:
Ø Treatment regimen




Ø Patient goals for adherence
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min. (with role play)
Activity 3: Group Activity: Case Studies
Participants will be asked to break up into groups. Participants will be asked
to discuss three case studies exploring adherence in preparatory counseling.
Group leaders will present key points of their discussion. Where additional
time is available, role-play can be done to enhance counseling skills.
Participants will be asked to use the checklists, patient literacy material and
pill demonstration chart. This session should take 60 minutes if role-play is
included.
Counseling Session 3 (contd)
Counseling Session 3 (contd)
Step 2: Assess patient treatment readiness
Ø Does the patient demonstrate an understanding of
his HIV disease and health status?
Ø Does the patient demonstrate an understanding of
his treatment regimen and follow-up?
Ø Does the patient appear to make a commitment to
take treatment long term?
Ø Does the patient have a major barrier to adherence?
Has that been addressed?
Ø Is he ready to start HAART?
Step 3:
Discuss patient readiness with physician
Refer patient to the pharmacy to receive ARVs
Step 4:
Set appointment for next visit
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Adherence Training Case Studies/Role Play
Case Study 1:  A 45-year-old man has been sent to you for counseling before
starting HAART. This is his first preparatory session. He has some information
on ARVs received from a radio program.  He has done primary school, lives
alone and still works full-time at a car repair workshop. He has not disclosed
his status to his family; his wife left him 5 years ago. He drinks alcohol most
evenings. He has a CD4 count of 160 cells and has had oral thrush, herpes
zoster and TB. Please conduct the first preparatory counseling session.
Case Study 2:  A 35-year-old woman has come for the third preparatory
counseling visit. She is eager to start her ARVs. She has studied up to primary
school and lives with her husband who is also infected but not on treatment.
She works part-time as a maid. She has a CD4 cell count of 96 cells but does
not understand what it means. She has had meningitis last month and was
hospitalized for 10 days. Discuss the counseling needs for this patient. Discuss
the use of dummy pills, a pill diary, reminder ‘cues’ and literacy material.
Assess her treatment readiness.
Case Study 3:  A 28-year old woman has come for her second preparatory
counseling session.  She works as a sex worker on the beachfront. She has a
CD4 count of 35 cells and has had PCP, herpes zoster and meningitis in the
last year. She is a widow, living in Bangladesh slum with two friends who
also work as sex workers.  She has completed high school. She has been
losing weight steadily, feels weak and finds it difficult to concentrate. She
has not been able to go to work for the last few weeks, as she has been
feeling unwell. Her friends have been supporting her. She is keen on starting
ART. She is planning to visit her family in upcountry next month.
If there is enough time, each group could conduct counseling for three cases.
Discuss:
§ Disease knowledge and status
§ Barriers
§ Factors that might influence adherence
§ Use of adherence enhancement tools—dummy pills, a pill diary, reminder
‘cues’ and literacy material.
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Prior use of ART
Determine social support






Review living conditions and employment
Housing
Employment/income
Describe the treatment program and importance of adherence
Drug regimen—name/frequency/storage/dietary instructions/not to share pills
What ART does—suppresses virus/improves immunity/less OIs/not a cure
Cost
Side effects and what to do
Follow-up
Importance of adherence and consequences of non-adherence
Discuss adherence promotion strategies
Buddy reminder—discuss role of support person
Pill diary
Other reminder cues
Identify barriers to adherence Yes No
Poor communication
Low literacy
Inadequate understanding about HIV/AIDS
Lack of social support
Failure to disclose status
Alcohol and drug use
Mental state
Schedule next counseling session and complete appointment card
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Date of counseling session....................................................................................................
Review client’s understanding of HIV/AIDS




Review the treatment program and importance of adherence
Drug regimen
Dummy pill demonstration
What ART does—improves immunity/less OIs/ART not a cure
Need for continued prevention
Side effects and what to do
Follow-up
Importance of adherence and consequences of non-adherence
Review proposed adherence promotion strategies
Buddy reminder—discuss role of support person
Pill diary
Other reminder cues—discuss DAART
Review barriers to adherence and progress made
Poor communication
Low literacy
Inadequate understanding about HIV/AIDS
Lack of social support
Failure to disclose status
Alcohol and drug use
Mental state
Take client’s address and establish contact system with treatment centre
Schedule next counseling session and complete appointment card
MODULE 3: Preparatory Adherence Counseling • 67










Date of counseling session....................................................................................................






Review the treatment program and importance of adherence
Drug regimen
Dummy pill demonstration
What ART does—improves immunity/less OIs/ART not a cure
Need for continued prevention—condom use
Side effects and what to do
Follow-up
Link between adherence and successful outcome
Review proposed adherence promotion strategies
Buddy reminder—discuss role of support person
Pill diary
Other reminder cues—discuss DAART
Fill ART register, schedule next appointment and complete appointment card
Refer to Pharmacy
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Prescriber/Physician Checklist after initiation of therapy
1. Have I determined, in collaboration with the patient, that s/he is ready to
start treatment?
2. Have I prescribed the simplest regimen?
3. Have I explained to the patient details about dosing of medications? Have
I reviewed with the patient any special instructions for taking and storing
the medications?
4. Is the dosing schedule compatible with the patient’s lifestyle?
5. Have I reviewed potential or common side-effects and considered
preemptive treatment of predictable adverse events?
6. Did I ask the patient to repeat the medication names, dosing times and
instructions?
7. Does the patient know how to contact the health-care team in case of
problems or questions?
8. Does the patient know where and when to collect his medications?
9. Have I fixed the next appointment?
(Promoting Adherence to HIV ART.
AIDS Institute, New York State Department of Health)
Activity 4: Review
Review the day’s discussion. Ask two volunteers to come up and present
main points for the day. Allow trainees to ask questions, seek clarifications
or additional information. Give out the additional reading material. Encourage








MODULE 3: Preparatory Adherence Counseling • 69








Module 3: Preparatory Adherence
Counseling
1. ADHERENCE COUNSELING: ITS NATURE AND PURPOSE
In HIV/AIDS-related counseling, two people who are in no way related to
each other meet to resolve a crisis, solve a problem or make decisions
involving highly personal and intimate matters and behaviour. A counselor’s
emotional detachment is the key in assessing a client’s case and providing
unbiased information on HIV/AIDS to the client. Additionally, counseling is
done during the pre- and post-test periods, after which patients may seek
care elsewhere and the counselor withdraws.
Adherence counseling on the other hand is a long-term requirement of patients
on ART. At this time, as scientific research stands, the virus cannot be
eradicated from the body; therefore, the disease cannot be cured. It has become
a chronic illness requiring management with medications. Anti-retroviral
therapy has to be taken long-term. As is with other chronic illnesses, adherence
to treatment changes over time and patients need support at different periods
during their treatment. Adherence counseling forms a relationship between
a counselor and client that is based on an understanding of the client’s life
situation and needs. This relationship is strengthened over time.
The objectives of adherence counseling are the following:
§ Help patients develop an understanding of their treatment and its
challenges.
§ Prepare the patient to initiate treatment.
§ Provide ongoing support for clients to adhere to treatment over the long
term.
§ Help clients develop good treatment taking behaviour.
§ Help patients in setting goals for their treatment.
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1.1 Attributes of a Good Adherence Counselor
Adherence counseling as mentioned above is a long-term requirement of
patients on ART. Adherence counselors need to have:
§ Ability to listen
§ Non-judgmental attitude
§ Ability to provide scientific, accurate and complete information on HIV
disease and antiretroviral treatment in an objective manner
§ Ability to encourage patients to take decisions, make commitments to
treatment
§ Ability to develop a long-term trusting relationship with patients
§ Problem solving ability
§ Ability to link patients with other support services.
1.2 Effective Counseling Techniques
Adherence counseling is a challenge. It hinges upon the ability of the counselor
to form a trusting and helping relationship with the patient. Counselors  also
need to have an in-depth understanding of ART (medications used, side
effects, viral resistance, adverse events etc.). Effective communication is the
counselor’s principal tool. An ability to understand the client’s life situation
(psychosocial, socio-economic, support systems, treatment seeking behaviour,
treatment readiness) and barriers to adherence is also essential.
Counseling should be done in a confidential setting where patients feel free
to discuss their problems, behaviours and barriers. Including a family member
in Sessions 2 and 3 may be useful to enlist social support only if the patient
is willing and has disclosed his/her status to the family.
Some effective counseling techniques are described below.
a. Active attending or listening
Paying attention to the client’s narrative helps in enhancing the client’s self-
respect, establishing a trusting relationship, in assessing the patient for
treatment readiness and in identifying some of the barriers to adherence that
the client may have.
b. Reflection of feeling
The counselor must recognize feelings such as anger, frustration, and sadness
or fear that are often associated with the illness (patients eligible for treatment
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are in an advanced stage of the disease with CD4 cell counts less than 200).
Some of these patients may have recently been tested and diagnosed with
HIV infection. These feelings further influence the patient’s ability to make
a commitment to take such treatment. The hope of treatment may push these
patients to make commitments quickly without understanding the challenges
of ART.
c. Questioning
Using questions to make communications clear so that both the problem and
the solutions are clear can be a useful tactic. For example: “Do you mean ...”
d. Paraphrasing
Many people can tell they are being understood accurately if the counselor
repeats what they have said in different words; for example, “You seem to be
saying that you are afraid your family is not going to take care of you.” The
client might then agree with the interpretation. If not, the counselor can clarify
the matter.
e. Interpretation
Often people avoid focusing on the real problem and talk around the issue.
Interpretation can be used to redefine the issue from a different point of view
or bring it out more clearly. The counselor can emphasize the important points.
For example, “Of all the things you talked about today, it seems to me that
you are most concerned about ...”
f. Repeating
At times of stress, people do not always understand everything they are told.
ART is a complicated treatment. Preparation of patients prior to initiating
treatment includes educating patients about the treatment regimen (names,
doses, dosing instructions), side effects to watch out for and the challenges
of treatment (such as the risk of treatment failure and viral resistance if taken
irregularly, monitoring of treatment and other drugs used for prophylaxis
and treatment of opportunistic infections). Repeating instructions may help
the patients to understand better as well as give the patient a chance to ask
questions or clarify doubts. Patients could also be asked to repeat instructions.
g. Summarizing
Summarizing the information given to the patient at the end of the meeting
is a form of repeating and paraphrasing the information once again. This
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provides the patient with the important points in a concise form that helps
the patient to organize the information and internalize it.
h. Respecting
It is important for the counselor to recognize that people see and cope with
their predicaments in uniquely personal ways. Counselors should respect the
patient’s views, beliefs, cultural context, and build on them.
i. Structuring or prioritizing and fixing goals
Antiretroviral therapy is a complicated treatment regimen that has to be taken
long-term. Medications have to be taken regularly, at fixed intervals with
dietary restrictions. This requires a disciplined and committed approach on
the part of the patients. Structuring means helping the patient to see how
actions and outcomes are related. Prioritizing helps patients determine what
needs to be done in which order so as to achieve the best outcomes. Counselors
can help patients to set goals (short- and long-term) and plan treatment
strategies for best outcomes.
2. PRE-TREATMENT ADHERENCE COUNSELING
Adherence counseling is challenging. It involves: (i) educating the patient
about ART, (ii) preparing the patient to start treatment, (iii) initiating treatment,
(iv) providing ongoing support counselling to help patients adhere to treatment
in the long term.
The preparatory phase prior to initiating ART requires at least two to three
clinic visits at an interval of 4–7 days. Some patients may require more than
3 preparatory counseling sessions. Baseline laboratory tests for initiating and
monitoring ART can be done during these preparatory visits.
The counseling sessions will be as follows:
Preparatory Counseling Session 1: Setting the groundwork for
adherence
Preparatory Counseling Session 2: Continued treatment and
adherence counseling
Preparatory Counseling Session 3: Assessment of patient
readiness and initiation of ART
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2.1 Preparatory Counseling Session 1:
Preparing the ground for adherence
The first preparatory adherence counseling session is used to assess the patient
as well as prepare the patient for initiating treatment. Adherence counseling
should be done in consultation with the treating physician who plans the
treatment. Establishing trust is the first step in preparing the ground for
adherence, to be built upon and strengthened at subsequent meetings. An
assurance of confidentiality, a non-judgmental attitude, mutual respect and
clear communication of information contribute greatly to developing a trusting
relationship.
The first session includes the following.
a. Patient assessment
The initial assessment of patients should include the following:
§ Learning about the patient’s health through a detailed medical history.
§ Learning about the prior use of antiretrovirals  and other medications.
§ Learning about the patient’s beliefs and attitudes about HIV and
treatment.
§ Learning about the sources of social support.
§ Learning about the socio-economic situation of the patient.
§ Identifying barriers to adherence.
This has been discussed in detail in Module 2. All information is to be recorded
in the patient adherence management charts.
b. Patient preparation for treatment readiness
Step 1: Introduction to the treatment and adherence program
Describe the treatment and adherence program.
Discuss the layout of the health facility including the laboratory and
pharmacy.
Discuss the system for treatment and follow-up:
§ Three counseling sessions prior to starting ART.
§ After starting ART the first two follow-up visits to be every two weeks
followed by monthly doctor consultations.
§ Laboratory tests. Some tests to be done every month, others every 2–6
months. The doctor will inform the patient about required investigations.
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§ Medications to be collected from the pharmacy after meeting both
counselor and physician. Monthly supply of drugs will be dispensed. The
patient must bring all medications with him/her at time of hospital visit.
Discuss payment issues for antiretroviral medications and laboratory
investigations.
Introduce staff (nurses, community health workers) who will be involved in
patient care.
Step 2: Discuss patients health status
i. Overall health
The counselor should assess the physical and mental health status.
§ Is the patient able to conduct routine daily activities—household
work, cooking, shopping, visiting friends or family?
§ Is the patient working?
§ Is the patient able to take decisions for him/herself about treatment,
where to live, what to eat, what to buy etc.?
§ Is the patient in control of his/her life?
ii. Current health status
Assess the disease stage of the patient. The treating physician will have
already done this during the screening process.
Discuss past opportunistic infections and hospitalizations and what it
implies in terms of disease stage and disease progression.
For example, if a patient has had cryptococcal meningitis, herpes zoster,
TB and candidiasis, and was hospitalized twice in the last 8 months, this
would imply advanced disease with low CD4 counts, Stage 4 disease
and severe immune suppression. The patient is already in the advanced
disease stage and needs treatment to prevent any further damage to the
immune system. The patient may perceive his HIV disease to be severe.
iii. CD4 counts
Discuss:
§ CD4 cell counts are a measure of the patient’s immune status, that
is, the body’s ability to fight infections.
§ HIV virus attacks CD4 lymphocytes and destroys them.
§ Normal CD4 counts should be between 600–1200 cells. (FHI/IMPACT 2003)
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§ Lower CD4 counts signify advanced HIV disease and more
opportunistic infections. Severe opportunistic infections occur when
CD4 cell counts decrease to below 200 cells.
§ There is good news! CD4 cell counts increase with treatment and
the body can once again start fighting off infections.
§ In order to increase CD4 cell counts patients need to take their
treatment correctly and regularly for the rest of their lives.
iv. Viral load tests
Discuss viral load tests when available and what VL implies in terms of
progression to AIDS. Discuss the following points:
§ Viral load measures the amount of HIV in the blood.
§ VL tests are very expensive and may not be available. Treatment can
be done successfully without using viral load testing.
§ In general, higher viral loads are associated with lower CD4 cell counts.
§ Viral load decreases with ART.
§ In order to achieve a decrease and maintain lower VL, patients need to
take their treatment correctly and regularly for the rest of their lives.
§ Higher viral load levels signify increased risk of transmitting infection.
§ Persons with higher viral loads can transmit infection more easily
to their partners through sex, through shared needles and through
blood and blood products.
§ A woman with higher viral loads can transmit infection more easily
to her unborn child in the womb, at the time of delivery and through
breast-feeding.
v. What can the patient expect to see with treatment?
Discuss that when treatment is taken correctly and regularly:
§ The virus is controlled.
§ Fewer CD4 cells are destroyed; as a result the CD4 cell count rises.
§ The immune system becomes strong enough to fight infections so
patients have fewer or no new opportunistic infections.
§ Patients feel better and stronger with an increase in body weight.
§ As the immune system improves, disease progress is prevented.
§ Treatment also reduces the chance of spreading infection.
vi. The importance of adherence to treatment
The importance of adherence to treatment and the consequences of non-
adherence. Discuss:
§ In order to control the virus you must take all your medications on
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§ If medications are not taken properly, missed or stopped in between:
• Medications stop working and are no longer effective;
• The virus can become resistant to these medications;
• CD4 counts start dropping and the viral load starts rising;
• Patients feel sick and lose weight;
• Old opportunistic infections can be reactivated or new infections occur;
• Patients need newer medications that are not available and are
very expensive;
• Patients can spread resistant infections to partners.
Use patient literacy materials on ARVs.
vii. Importance of protective and preventive behaviour
It is extremely important to continue practicing safe sex (use condoms) because:
§ Patients with HIV infection can still become infected with a new strain
(type) of HIV virus. This is called ‘re-infection’.
§ The new virus can worsen their disease and hasten disease progress.
§ Patients can also transmit resistant infections to their partners.
§ Patients with advanced disease and higher viral loads can transmit
infection more easily.
§ Using condoms is very important to prevent transmission of infection to
others and to protect oneself from getting infected with a new strain of
HIV virus.
viii. Pregnancy and use of oral contraceptives
It is important to ask lady patients about family planning methods they use
and about the possibility of being pregnant or planning a pregnancy.
Oral contraceptives interfere with the metabolism of certain antiretroviral
medications and may require a change in family planning method or the
antiretroviral medication used. For example, patients would need to use
alternative family planning methods with Lopinavir, Amprenavir, and
Ritonavir etc.
Intra-uterine devices such as the Copper T or Lippes Loop may increase the
chance of pelvic infections as well as transmission of HIV infection.
For patients who are pregnant or planning a pregnancy, medications like
EFV cannot be used due to risk of fetal malformations. Treatment regimen
for these patients should include AZT and NVP, which have been tried and
tested for prevention of mother-to-child transmission of infection. Patients
would need additional counseling on prevention of mother to child
transmission of HIV infection and services available.
(FHI/IMPACT 2003)
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Step 3: Review patient living and work conditions
§ Employment and work routine: To identify barriers to taking medications
regularly.
§ Daily routine—eating and sleeping pattern: To identify ways to integrate
treatment into the daily routine without much disruption.
§ Access to food and income: Patients need good nutritional intake to fight
the HIV disease. Patients without income, access to food, the means to
meet their basic needs, would require additional support, such as linking
with food donation services or income generation activities etc.
§ Travel routine: Patients who travel for work (migrant workers) or for other
reasons would need to prepare to take adequate supplies of medications.
§ HIV confidentiality issues at place of work and at home: These influence
regular intake of medications. Patients may not be able to take medications
in the presence of family or colleagues. Patients may not be able to store
medications suitably if they need to hide them.
Step 4: Establish a treatment plan
Discuss the treatment regimen.
§ Medications: Discuss the number of ARV medications, the names and
dose of medications, show the patient demonstration pills and ask the
patient to repeat the names and doses.
For example, ‘You have to take three ARV medications: Zerit 40 mg, one
capsule two times a day, Epivir 150 mg, also one tablet two times a day
and Stocrin 600 mg, one capsule once a day at night before sleeping.
Please could you repeat what I just told you?’
§ Dosing: Number of doses and time intervals.
§ Instructions on food and fluid intake/restrictions.
For example, ‘You should take Zerit by mouth with a glass of water in
the morning at 8 am and in the evening at 8 pm. You may take this
medication with or without food.’
§ General instructions should include:
a. These medications are meant only for you. Do not share them with
others. If you share them, neither of you will benefit.
b. Take all doses on time so that the medicine can have its full effect
and the virus is controlled.
c. Continue to take these medications, even when you feel better. These
medications do not remove the virus from the body. They can only
control the virus. Therefore you need to take these or similar
medications for the rest of your life.
d. If you do not take them exactly as prescribed or miss doses, the medicines
may stop working and the virus may become resistant. You will then
need to take new medications, which may not be available.
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§ Storage of medications. Patients should be advised on how to store
medications.
a. Keep these medications in a cool, dry and dark place—like a drawer
or cupboard. Do not keep them near the kitchen sink or in the
bathroom.
b. Heat and humidity can spoil the medications.
Side effects: These need to be briefly touched upon during this session. Too
much information during the first counseling session will overwhelm the
patient and may negatively influence commitment to start treatment.
Discuss the follow-up plan
§ Clinic visits. Discuss the follow-up plan.
• Frequency of visits to clinic—for example first four visits after
starting ART to be every two weeks, then once every month.
• Where the patient needs to report during clinic visits—for example
at the reception counter of the health facility.
• How to fix new appointments or change appointments if s/he cannot
come for a scheduled visit.
§ Counseling sessions. Inform the patient about the next two counseling
sessions. Inform that they are free to discuss their problems, concerns or
doubts about medications. Counseling is an opportunity for patients
to learn about their treatment and ask questions.
Fig. 3.1: Pill demonstration chart
MODULE 3: Preparatory Adherence Counseling • 79







§ Pharmacy refill. Discuss the pharmacy refill procedure and location of
the pharmacy. Inform the patient that s/he needs to meet the counselor
and the doctor before proceeding to the pharmacy.
§ Laboratory monitoring. Discuss the need for laboratory monitoring,
process for lab investigations as advised by the doctor and locations of
the laboratories.
It may be useful to ask for a rapid follow-up session 48–72 hours after the
patient starts therapy to assess understanding of medication schedule and
dose.
Step 5: Discuss the proposed adherence strategy
Discuss the adherence promoting strategies to be used for the patient: calendar
based pill diary, treatment reminder cues, modified DOT, buddy system etc.
Step 6: Identifying barriers to adherence
The treatment preparation process should ensure that potential or actual
barriers are identified. During discussions with the patient, identify potential
barriers. The patient and provider can work together to address these barriers
at the patient level, while the health system can address the barriers at the
service delivery level.
Barriers and ways to address them have been discussed in detail in Module
2.
Step 7: Fix a date for the next appointment.
Note:
• Avoid information overload. Patients may not be able to
assimilate too many details in the first session.
• Use simple language and terms.
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2.2 Preparatory Counseling Session 2:
Continued Treatment and Adherence Counseling
Step 1: Review and assess patients understanding of his/her
HIV disease stage and related treatment issues
(a) Current health status:
(i) Disease stage: Past opportunistic infections and what that implies
in terms of disease progression.
Does the patient understand his/her disease? The aim is not to depress
the patient further but for them to see it as an opportunity to reverse
the illness and slow disease progress.
(ii) CD4 counts: Does the patient understand what his/her CD4 count
means and what it implies in terms of disease progression?
(iii) Viral load (if available): Does the patient understand what his/her
viral load means, if it was done, and what it implies in terms of
disease progression?
(b) What results can the patient expect to see with treatment? Review patient
knowledge. Emphasize the connection between regular and correct
treatment taking with effectiveness of medication, improving immune
function, higher CD4 counts, lower viral load readings, fewer
opportunistic infections and slowed progression to AIDS.
(c) The importance of adherence to treatment and the consequences of non-
adherence.
Use patient literacy material on ARVs.
Note:
1. The approach should be of a continuing discussion on issues related
to treatment.
2. Repeat information wherever necessary.
3. Re-emphasize key messages.
4. Discussion should be done in a non-judgmental way and should
not appear to be an inquiry or evaluation of knowledge.
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Step 2: Review and assess patients understanding and
recall of the treatment plan
(a) Review the treatment regimen.
§ Medications
§ Dosing
§ Instructions on food and fluid intake
§ Storage of medications.
(b) Use dummy pills to repeat instructions for the patient.
Step 3: Review plan for treatment follow-up
(a) Discuss potential side effects and plan for a response.
Provide greater details on this topic in this session. This should be done in
collaboration with the treating physician. Discuss:
§ What side effects to expect in the short-term;
§ How to manage side effects if and when they occur;
§ When to seek care—danger signs to watch out for;
§ Who to contact—where to go for management of side effects, names of
health workers to contact.
Use patient literacy material on side effects.
(b) Discuss the plan for routine follow-up.
Plan for follow-up visits: every two weeks for the first four visits and
then a monthly follow-up.
(c) Establish a contact system.
Patients should have clear instructions on how and where they can contact
the provider in case of need: medication side effects, illness etc.
§ Note patient’s detailed address including nearby landmarks so that patient
can be contacted if required (in case of missed appointments).
§ Patient’s contact telephone numbers should be taken.
§ Nurse counselor’s telephone contact number should be provided to the patient.
§ Set time, location and contact plan with the patient.
(d) Help patient set goals.
All patients may not have the ability to take medications on time and regularly.
Setting goals for adherence helps treatment-naïve patients to start treatment
with commitment and helps treatment-experienced patients to improve
treatment taking and adherence.
(FHI/IMPACT 2003)
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Setting short-term goals (for the next 1–2 weeks) for medication intake.
For example, the patient aims to achieve 100% medication intake over the
next 1–2 weeks. This allows the patient to set an achievable goal, build
confidence and helps the patient to commit him or herself to a treatment and
adherence plan.
Setting long-term goals (for the next 6 months or year) for health outcomes
may help patients take a long-term view of their treatment plan and resulting
successful health outcomes. For example, take medications to achieve 10%
weight gain, or to increase CD4 cell counts, or to prevent new opportunistic
infections over the next 6 or 12 months.
Discuss treatment reminder ‘cues’ such as linking medication intake to
meal time or leaving for work, placing notes at strategic points at home or
office, keeping medications at visible locations at home etc.
(e) Integrate treatment into patients daily routine of activities.
To be effective, ARV medications have to be taken on time, regularly and
over the long term. This could be a lifestyle change for patients. A discussion
on integrating medication intake with the patient’s daily routine is extremely
important—this serves to establish a participatory approach to planning and
helps patients take their medications on time and regularly.
Review the patient’s daily routine and the plan to integrate treatment into the
daily routine. For example:
Patient G K
Morning dose of D4T and 3TC at 8 am just after breakfast before
leaving for university.
Evening dose of D4T and 3TC at 8 pm after dinner.
EFV to be taken between 10–11 pm, before going to bed.
D4T and 3TC to be kept near the dining area and EFV on bedside table.
Step 3: Discuss the proposed adherence strategy
The counselor should discuss the adherence promoting strategy to be used
for the client. The use of the pill diary and treatment reminder ‘cues’ should
be discussed as part of the treatment plan. Patients should be encouraged to
involve family members in helping them to adhere to the treatment.
Step 4: Review barriers to adherence
Review barriers to adherence identified during the first preparatory visit.
Assess if those barriers require further counseling or intervention. Review
progress made.
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2.3 Preparatory Session 3: Assessment of Patient
Readiness and Initiation of ART
To be properly prepared to start ART, patients generally require 2–3 meetings
with the adherence counselor. Some patients may need more than three
couseling sesstions. At the third counseling visit the treating physician and
nurse counselor should assess patient readiness to initiate treatment. Patients
who appear to be ready and committed can start therapy.
Step 1: Review the treatment and follow-up plan in detail
(a) Review the treatment regimen.
§ Medications
§ Dosing
§ Instructions on food and fluid intake
§ Storage of medications
§ Use dummy pills to repeat instructions for the patient.
(b) Discuss potential side effects and plan for a response.
§ Which side effects the patient can expect to see
§ How to manage them
§ When to seek care
§ Where to go.
(c) Discuss the follow-up plan for routine follow-up.




(d) Discuss the adherence strategy.
§ Routine monthly visits for follow-up
§ Pill diary/pill box/treatment buddy/family support etc.
§ Medication refills—pharmacy appointments
§ Missed appointments, contact plan, and home-tracing plans.
(e) Review contact system.
(f) Review patient goals for his/her health.
§ Short-term goals for medication intake
§ Long-term goals for health outcomes.
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Step 2: Assessment of patienttreatment readiness
It may be best to initiate treatment once the patient demonstrates an
understanding of the disease, of the treatment and the link between adhering
to treatment and successful treatment outcomes (such as improved immune
status, increasing CD4 counts, decreasing viral load etc.) and when the patient
is able to make some commitment towards long-term treatment and adherence
to treatment.
§ Does the patient know his treatment regimen? Does s/he understand
dosing and dietary instructions?
§ Does the patient demonstrate an understanding of his disease?
• HIV infection and disease stage
• Treatment is not a cure
• CD4 count—patient level and what it implies, expected change with
successful treatment
• Viral load.
§ Does the patient understand the link between good adherence and
successful treatment: improved immune status, increasing CD4 cell
counts?
§ Has the patient demonstrated a commitment to taking medication long-
term?
§ Does the patient have a major barrier and has that been addressed?
§ Is the patient ready to start treatment?
The counselor and physician determine whether the patient is ready to start
treatment and refer the patient to the pharmacist with a prescription.
Step 3: Refer to the pharmacy to provide ARV medications
The pharmacist reviews the medications and instructions with the patient
and provides medications. Pharmacists also counsel the patient on medication
intake, adherence and side effects.
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§ To provide trainees with skills in ongoing adherence counseling
§ To provide trainees with skills in problem solving
ACTIVITIES
1. Presentation and discussion on ongoing adherence counseling60 min.
2. Role play 60 min.
3. Review or summary 15 min.
2 hour 15 min.
HANDOUTS
1. Additional reading material on Ongoing Counselling: Module 4
2. Patient literacy materials
3. Checklist for ongoing counseling
Activity 1: Presentation and Discussion
The presentation will discuss problem solving with a focus on medication-
related side effects, disease progress, illnesses, and psychosocial problems.
The trainer or presenter will use this session to encourage discussion in the
form of an interactive session. Participants will be encouraged to discuss
problems they face when managing patients in their clinics with a focus on
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At the end of this session participants
should have a basic understanding of
Ø Problem solving
Ø Addressing side effects
Ø Assessing and supporting adherence
Ongoing Adherence Counseling
Challenges:
Ø Barriers change over time
Ø Multiple factors influence adherence at any time
Ø Adherence changes over time
Although counseling needs change over
time, the approach remains the same!
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Adherence from pill counts:
p
# pills should have taken
  100  % Adherence
×
Adherence from self report:
% Adherence over last 4 days =
# doses should have taken  # missed doses
# doses should have taken
  100×
Step 1: Review and assess adherence
over last month
Ø Medications




 Taken all doses
 Taken on time
 Reasons for missing dose
 Complete pill count and self report
Ø Difficulties or side effects experienced
Away from home Forgot/Busy Slept in
Felt ill Ran out of pills
Side effects
Felt better
Fear of side effects
Pills do not help
Did not want
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WHAT  WE CAN DO
Collect meds in advance
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Missed appointments (sick, distance)
Ø Send tracer CHW
Ø Reminders, Phone call
Ø Change to nearest treatment site
Missed Doses
Ø Do not take a double dose
Ø Within 3 hours of scheduled dose take the missed dose
Ø If > 3 hours of scheduled dose, miss dose and go on to




Ø Counsel, support the patient
Ø Manage side effects
Ø Enlist family support
Side effects
Ø Discuss how to address them at start of ART as well as
during treatment
Ø Inform patients when to seek medical care
Ø Use patient literacy materials
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Side effects: Nausea and vomiting
Ø Commonly seen with AZT, DDI and Kaletra
Ø Usually transient and resolves in  24 weeks
Ø Refer to the physician:
Ø If severe abdominal pain, respiratory difficulty and
disorientation  may be a sign of lactic acidosis
Ø Severe abdominal pain may also be a symptom of
pancreatitis
Ø If patient is dehydrated
Ø If fever, headache, disorientation, altered
consciousness  may indicate meningitis and not ADR
Advice to patients
Ø Take with food if permitted
Ø Eat more frequent small meals
Ø Avoid greasy, spicy and fatty foods. Take bland lightly
cooked food  rice, soups, bananas, biscuits
Ø Drink sips of clean boiled water, weak tea, and lemon
water. Maintain hydration
Ø Contact nurse or doctor in case of fever, vomiting more
than three times/day, thirsty but unable to drink, pain in
abdomen, breathlessness, confusion
Side effect: Headache
Ø Usually transient and passes over 24 weeks
Ø If accompanied by fever, disorientation, altered
consciousness or convulsions may indicate
meningitis, encephalitis or space occupying
lesion  refer patient to physician
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Ø Rest in a quiet, dark room
Ø Place cold cloth over eyes and forehead
Ø Avoid strong tea or coffee
Ø If not relieved with 45 doses of Paracetamol,
consult health worker
Ø If frequent and severe headaches or fever,
vomiting, altered consciousness, blurred vision or
convulsions contact a nurse or doctor immediately
 Side effects: Diarrhea
Ø Usually transient and passes over 24 weeks
Ø Refer to the physician
Ø If blood or mucus or fever refer to physician
to treat infection
Ø If severe diarrhea
Ø More than 5 times per day
Ø 5 or more consecutive days
Ø Weight loss of more than 2 kg
Advice to patients
Ø Eat small meals more times a day
Ø Eat soft, easy-to-digest food  rice, bananas,
biscuits. Avoid greasy, spicy and fatty foods.
Ø Drink sips of clean boiled water, weak tea, ORS,
lemon water. Avoid orange juice or very salty soups
as they can increase diarrhea.  Maintain hydration.
Ø If fever, mucus or blood in stools, diarrhea more
than 45 times a day for 5 or more days, contact
nurse or doctor
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Ø Rashes mostly seen with NVP, EFV, Abacavir
*Any new medication may cause allergic rash
Ø Mild rash and itching can be treated with
antihistamines and calamine lotion
Ø Severe rash (peeling of skin, watery discharge,
blistering, and ulceration)  requires immediate
physician referral and removal of medication
Ø Keep skin clean and dry
Ø Use mild soaps
Ø Drink plenty of water to keep skin hydrated
Ø Antihistamines to relieve itching and rash
Ø Use Calamine lotion
Ø If peeling of skin, blistering, or ulceration
contact nurse or doctor immediately
Side effects: CNS Symptoms
(Nightmares, sleeplessness, sadness or worry)
Ø Mostly seen with EFV
Ø Usually transient and disappear in 24 weeks
Ø EFV at bedtime reduces symptoms
Ø If severe depression, loss of interest or suicidal
ideas, refer to the physician and counselor
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Ø Usually temporary and will resolve in few weeks
Ø Take EFV at bedtime
Ø Avoid heavy meals before sleeping
Ø Avoid alcohol, drugs
Ø Talk about your feelings with your friends or family
Ø If feel very sad, have thoughts of killing
yourself, contact a nurse or doctor immediately
Side effects: Fatigue
Ø Fairly common
Ø Multiple causes  HIV infection, medications,
depression, anemia
Ø Regular and restful routine helps to reduce
fatigue
Ø Alcohol and use of recreational drugs worsen
fatigue
Ø Avoid alcohol, tobacco, Miraa and other
recreational drugs
Ø Light physical exercise may help
Ø Balanced diet with fruits and vegetables
Ø Consult nurse or doctor if feel very depressed
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Side effects: Numbness, tingling or burning
Ø Mostly seen with D4T, DDI
Ø Other ARV medications and INH, Rifampicin can also
cause neuropathy
Ø If severe and associated with weakness and inability
to walk  refer to the physician. Medications may
need to be changed
Ø Usually non-reversible
Ø Vitamin supplements and antidepressants may relieve
symptoms
Ø Protect your feet
Ø Wear loose fitting shoes and socks
Ø Keep feet uncovered in bed
Ø Soak feet in warm water, massage feet
Ø Dont walk too much at a time
Ø Inform health worker
Side effects: Change in appearance
Ø Lipoatrophy/Lipodystrophy  fat redistribution
Ø Usually seen after several months treatment
mostly with D4T and PIs
Ø Usually not reversible
Ø Limited treatment available
Ø When associated with metabolic disturbances like e.g.
hyperlipidemia or hyperglycemia, regimen may be
changed
Ø Management of diabetes and hyperlipidemia required
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Ø Hepatitis, pancreatitis, renal dysfunction, anemia,
metabolic disturbances like hyperglycemia or
hyperlipidemia are diagnosed through laboratory
tests
Ø Refer to the clinician for management when any
of the above seen
Ongoing counseling
Step 2:
Ø Discuss the follow up plan
Ø Review upcoming travel plans, contact
information
Ø Review patients goals. Set new goals
Step 3:
Set up appointment for next visit
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Activity 2: Group Activity: Role Play
Participants will be asked to break up into groups. Participants will be given
cases to discuss and role-play. This activity is designed to enhance counseling
skills. Patients will be asked to use the ongoing counseling checklist and
patient literacy material to facilitate counseling. This activity will build on
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Adherence Training Role Plays
Role Play 1
An 18-year-old Matatu tout with symptomatic HIV infection is started
on first line ART (3TC/D4T/EFV) and is being followed by Directly
Administered ART (DAART) at CPGH. He has had TB and cryptococcal
meningitis last year. He lives with his girlfriend in the suburbs and has
just recently disclosed his HIV status to his girlfriend, so she knows about
his treatment. He consumes moderate amounts of alcohol. At his 3-
monthly visit it is noticed that he has failed to attend DAART on two
occasions in the last month. His home district is Kitui. He has been
complaining of numbness and tingling in his feet.
Discuss the implications of this non-adherence and your adherence-
counseling plan highlighting the issues (side effects, travel, change in
routine, depression, alcohol), which should be discussed.
Role Play 2
Mwanahidi is a 40-year-old widow who lives in the Majengo slum with
her four children. She is on first line therapy (3TC/D4T/EFV) and fails
to come to her second routine monthly clinic visit. The community health
worker visits her at home. She is unkempt and neighbours report she has
become quiet, sad and withdrawn. She has not been eating anything
because of nausea and vomiting. She is also complaining of pain in her
abdomen. Her CD4 count was 23 cells at the time of starting ART. She
has had TB and herpes zoster before starting ART.
Discuss the implications of this non-adherence and your adherence-
counseling plan, highlighting the issues which should be discussed.
Conduct the session.
Role Play 3
Tom is a 40-year-old barman in a city hotel. He lives alone. He started
ART (3TC/D4T/EFV) seven months back. He has attended all his monthly
appointments until the last two months when he has had to be traced by
a community health worker. He has been drinking heavily and says he is
feeling better so has stopped treatment since last month. He had been
complaining of changes in his appearance, sunken cheeks and fat around
his abdomen. Liver function tests show raised SGOT/PT levels.
Discuss your adherence-counseling plan highlighting issues relevant to
this case. Conduct the session.
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COUNSELING SESSION FOLLOW UP
Client’s name .................................................................................................................
Date of counseling session....................................................................................................
Review the patient’s experience with treatment and adherence over the past month
Drug regimen and adherence—pill counts, self report
Discuss side effects and actions taken
Discuss need for continued prevention
Review experience with follow-up plan
Discuss follow-up plan for next month
Review patient’s goals and success at achieving them
Review barriers to adherence
Buddy reminder—discuss role of support person
Review pill diary
Review barriers to adherence
Poor communication
Low level of literacy
Inadequate understanding of HIV/AIDS
Lack of social support
Failure to disclose status
Alcohol and drug use
Mental state








Activity 3: Review. Q and A.
Ask two volunteers to come up and present main points for the day. Allow
trainees to ask questions, seek clarifications or additional information. Give
out the additional reading material. Encourage trainees to read material and
discuss issues the next morning.
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1. FOLLOW-UP COUNSELING AND ONGOING SUPPORT
Adherence levels change over time as patients get accustomed to their
treatment, face new challenges, experience side effects or feel better.
Counseling needs to change as well over time. Different patients require a
different level of ongoing support, necessitating a patient-centered
individualized approach.
In resource-constrained settings with staffing shortage, providing ongoing
support and follow-up counseling may not be possible for all patients.
Counselors need to be aware of potential barriers a patient may face and be
available to provide support when necessary. Ongoing counseling may be
reserved for the most vulnerable clients and needs to be patient-centered and
individualized.
1.1 Follow-Up Counseling Session
Step 1: Review and assess the patients experience with
treatment and adherence over the past month
(a) Review the treatment regimen.
§ Review medication names and any change in treatment regimen.
§ Dosing instructions—during the early follow-up period or if new
medication has been added.
§ Instructions on food and fluid intake—during the early follow-up period
or if new medication has been added.
§ Storage of medications—during the early follow-up period or if new
medication has been added.
(b) Discuss adherence.
§ Discuss medications taken.
§ Complete pill count and self-report. Assess adherence (Box overleaf).
§ Determine reasons for missed doses. Discuss ways to address problem
areas.
(c) Discuss side effects experienced and actions taken.
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Adherence from Pill counts
% Adherence = 
   # of pills patient should have taken – # of pills missed  
 ×   100
# of pills patient should have taken
Name of Number of Number of pills Number of pills Number of % Adherence
medication pills patient expected to patient actually pills missed
dispensed have taken took A – B  
×  100(A) (B)  A
(Take into account (Take into
whether patient has account remaining
come early, on time pills and whether
or after the refill due patient has come
date) early, on time or
after the refill due
date)
E.g. 60 54 50 4 54 – 4 
×  100d4T (10 pills remaining  54
One tablet (For 30 (Patient came in when they should =92.5%
taken twice days) 3 days early) have been only 6)
daily
Adherence could be < 100% when patients have taken fewer pills than required or > 100% when they have
taken extra pills by mistake.
Adherence from Self-Report
Adherence measured using a self-report will only reflect the adherence over the period of recall; e.g. 3 days
in the table below.
Patients should be asked about missed doses: How many doses of d4T did you miss – yesterday, the day
before that and the day before that (3 days ago)?
% Adherence = 
# of doses patient should have taken – # of doses missed 
 ×  100
# of doses patient should have taken
Names of Yesterday Day before The day before % Adherence
Medications yesterday that (3 days back)
(Missed doses) (Missed doses) (Missed doses)
E.g. d4T 0 1 1 6 – 2 
×  100 = 67%One tablet 6
taken twice
daily
MODULE 4: Ongoing Adherence Counseling • 103







§ Advise patient on how to manage short-term and mild side effects. For
serious side effects refer to the physician. (Discussed in detail later in
this module.)
§ In collaboration with the physician, set up ways to address side effects.
Identify problem areas.
§ Review when to seek care, how to contact providers.
(d) Review the experience with the follow-up plan.
§ Problems faced with the follow-up plan. For example, the patient is unable
to attend clinic on scheduled days because of travel upcountry, working
overtime so could not collect medications etc.
§ Develop new strategies to address problem areas and barriers.
(e) Discuss the follow-up plan for routine follow-up.
§ Enquire about any proposed travel—the patient should inform in advance
and collect extra supply of medications prior to travel.
§ Enquire about any change in life conditions: change in address, financial
problems, separation or divorce, pregnancy, new child, death of a loved
one, etc. Do not ask specifically about each one, allow the patient to tell
you. Probe.
§ Review contact information.
(f) Review patient goals and patients success with
achieving them.
§ Was the patient able to achieve his goals?
§ What to do to achieve them next time?
§ Set new goals. For example, over the next two weeks the patient will try
to get up early and take all his medications within 2 hours of the due
time; will use an alarm clock.
§ Integrate treatment into the patient’s daily routine of activities.
(g) Review barriers to adherence.
Review the barriers to adherence identified earlier and new barriers that have
come up and success in addressing them. These may change during the course
of treatment—the patient may start drinking, may be thrown out of home,
may face economic loss, loss of employment, travel and movement etc.
Problem solving is discussed later in this module.
Step 2: Complete the required data collection forms
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a. Practical problem solving
Patients may not take their medications for several reasons. Problem solving
relates to finding out the cause for missing medications and addressing those
reasons/barriers. The table below lists some of the common reasons patients
cite for missing doses, possible barriers and suggestions on problem solving.
Reasons for missingPossible barriers Problem solving
doses given by
patients
Forgot to take pills Patient forgot because:
• Traveling
• Alcohol/active drug use
• Depression/psychiatric
illness
• Living alone and sick
• Homeless, no family
support
• Plan before travel, take
extra pills
• Use reminder cues
• Address addiction
(alcohol and drugs)
• Enlist family support
• Treat depression
• Use PLHA support
groups
Pills do not help
Felt better so did
not continue
• Inadequate knowledge






• Enlist family support
Family said no to
medications
• Inadequate knowledge














• Alcohol/active drug use
• Insufficient time to
counsel
• Use literacy materials
• Use dummy pills and
repeat instructions
• Ask patient to repeat
instructions
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Patients may miss appointments for several reasons ranging from travel
outside their place of residence, being busy with other things, forgetting,
employment, confidentiality issues, distance from the health center, economic
problems or being too sick and unable to travel.
§ Identify barriers and ways to address them. Patient participation may be
necessary to ensure continuing medication intake and adherence to
treatment.






• Use PLHA support
groups
• Register with the
home-based care
program
• Link with FBO
food donation
programs
• Locate family and
enlist support
• Identify a friend who
could help
Did not want others
to see patient taking
medications
• Stigma at place of work
• Non-disclosure in the
family
• Provide counseling
support to help with
disclosure
• Identify a friend who
could help keep
medications




to expect and how to
manage it
• Counsel on risks of
non-adherence
Table Continued.
Reasons for missingPossible barriers Problem solving
doses given by
patients
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§ Provide additional counseling support.
§ Establish a system of ‘tracers’  or a way to contact patients at home to
prevent non-adherence with chronic defaulters.
§ Adapt the service delivery system to overcome systemic barriers—a client-
friendly clinic, flexible hours, ‘one-stop shop’ (that is adjusting
appointments so that patients could complete all required appointments
with physician, counselor, social worker, psychiatrist, dermatologist,
neurologist as required during the same hospital visit).
§ Setting goals to not miss appointments.
§ Planning before travel so that the patient can take an extra supply of
medications with him/herself.
c. Missed doses
Reasons for missing doses may vary from simply forgetting, travel, work
hours, running out of pills, sharing medications, being unable to get to the
clinic, not understanding instructions, feeling better, family pressure not to
take medications etc. Most of these reasons are linked to barriers that the
patient faces. Identifying and addressing barriers has been discussed in Module
2.
Patients can be given the following advice:
§ Do not to take two doses at one time.
§ Do not take the missed dose close to the time of the next dose.
§ Take the missed dose if within 3 hours of the scheduled time.
§ Drop the missed dose and take the next dose on time if after 3 hours of
scheduled dose time. Carry on with the treatment schedule. Mark the pill
diary for the missed dose with the reason for missing medication.
§ If severe side effects occur, inform the physician or adherence counselor
or health worker.
d. Reminders
When follow-up visits are far apart, patients may need to be reminded about
the clinic appointments. This could be done through the local community
health worker network, sending letters or appointment cards, using family
members to keep track of clinic appointment or through phone calls.
e. Medication regimen related problems
Patients may find themselves unable to cope with some of the side effects
related to medication intake, burden of pills to be taken, complicated
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instructions etc. In some cases physicians may be able to change the regimen
to include preparations that contain two or three medications in a single pill
(fixed dose combinations) thus reducing the number of pills to be taken.
With newer preparations coming into the market, once-a-day dosing could
also be considered. This is best done at the start of treatment.
In resource-constrained settings the choice of drugs is often limited and this
may not be possible.
f. Pill fatigue and drug holidays
Patients who have been on treatment for a some time may experience problems
related to taking a large number of pills. They may get tired of taking
medications every day or feel overwhelmed—‘pill fatigue’. In western
countries patients have been known to take ‘drug holidays’—that is stop
taking medications for a few days, e.g., weekends or during holiday travel.
While this may not be seen yet among patients in developing country programs
it is useful to keep it in mind when following-up patients on ART. This
should be discouraged!
g. Side effects
These may range from short-term side effects to more delayed long-term
effects. Short-term side effects generally disappear over 2–6 weeks. Patients
should be supported through this period and encouraged to continue. Family
support and sometimes peer group support (where patients are willing to
disclose/share status) may be helpful. Setting short-term goals also helps
patients to keep taking medications.
Management of long-term side effects or adverse events is to be done by the
treating physician; nurse counselors should refer the patient to the treating
physician. Physicians may need to change the ARV medication or prescribe
specific treatment such as oral hypoglycemics or insulin for diabetes, lipid-
lowering medications for hyperlipidemia. Future management should be done
in collaboration with the physician.
(i) Nausea and vomiting
§ Nausea and vomiting are commonly seen with NRTIs: AZT, DDI and
with Protease inhibitors: Kaletra, Crixivan, Ritonavir, Saquinavir etc.
Nausea and vomiting can also be seen with any new medication that a
patient may take. Nausea and vomiting associated with ART is usually
temporary and passes in 2–6 weeks. Patients should be supported during
this period till the symptoms abate.
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§ The patient should be asked to consult the physician or nurse if vomiting
is accompanied by severe abdominal pain, respiratory difficulty and
disorientation, as the patient may be suffering from lactic acidosis.
§ Severe abdominal pain could also be a sign of pancreatitis.
§ In the case of severe vomiting, more than 5–6 times for more than one
day, the patient may develop dehydration (dry tongue, loose skin, listless-
ness, thirst, not passing urine), and should consult the physician or nurse.
§ If vomiting is accompanied by fever, headache, disorientation, or altered
consciousness, patients should be advised to consult the physician or
nurse as they may be suffering from other conditions such as meningitis,
encephalitis, lymphoma or toxoplasmosis.
The patient can be given the following advice:
§ Follow doctor’s instructions; ask if medications can be taken with food.
§ Eat more frequent small meals.
§ Avoid greasy, spicy and fatty foods. Take bland, lightly cooked food—
rice, soups, bananas, biscuits.
§ Drink sips of clean boiled water, weak tea, and lemon water. Maintain
adequate hydration.
§ Contact nurse or doctor in case of fever or blood in vomit, if vomiting
continues for more than one day, thirsty but unable to drink, not passing
urine, disoriented or unconscious.
(ii) Headache
Headache is most commonly seen with AZT, 3TC, d4T, DDI, Crixivan,
Saquinavir and NVP. Headache can also be seen with any new medication. It
is usually transient and passes over 2–6 weeks as the body gets used to the
new medications. If headache is accompanied by fever, disorientation, altered
consciousness or convulsions it may indicate meningitis, encephalitis,
lymphoma or toxoplasmosis and requires immediate consultation with the
physician.
The patient can be given the following advice:
§ Use balm or rubs to relieve headache. Gently rub temples and back of neck.
§ Rest in a quiet, dark room with no disturbance.
§ Place a cold cloth over eyes and forehead.
§ Avoid strong tea or coffee. Avoid items that trigger headaches.
§ Take a paracetamol tablet if not improving with rubs.
§ If not relieved with 4–5 doses of paracetamol, consult nurse or doctor.
§ If frequent and severe headaches, fever, vomiting, altered consciousness,
blurred vision or fits occur, contact the doctor immediately.
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Diarrhea can occur with d4T, DDI, Kaletra, Crixivan, Ritonavir, Saquinavir
and EFV. It is usually transient and passes over 2–4 weeks. Patients need to
seek medical attention if diarrhea is accompanied by blood, mucus or fever,
as this may be due to an intestinal infection requiring treatment. Patients
would also need to seek medical advice if severe diarrhea occurs—more
than 5 times per day, for 5 or more consecutive days, or results in weight loss
of more than 5 lb.
The following advice can be given to the patient:
§ Eat small meals more times a day.
§ Eat soft easy to digest food—rice, bananas, biscuits. Avoid greasy, spicy
and fatty foods.
§ Drink sips of clean boiled water, weak tea, oral rehydration solution
(ORS), lemon water. Avoid orange juice or very salty soups as they can
increase diarrhea. Maintain hydration.
§ If diarrhea is accompanied by fever, mucus or blood in stools, or is more
than 4–5 times a day, contact the nurse or doctor.
(iv) Rash
Rashes are mostly seen with NVP, EFV and Abacavir. It is important to keep
in mind that any new medication or ARV can also cause allergic rashes.
Mild rash and itching can be treated with antihistaminic medications and
calamine lotion. Severe hypersensitivity reactions with peeling of skin, watery
discharge, blistering, and ulceration requires immediate physician referral
and removing of offending medication as this can be a life threatening
hypersensitivity reaction or Steven Johnson syndrome. The offending
medication should not be restarted after such a strong reaction. With NVP,
rash may accompany liver disturbances requiring a change of medication.
The patient can be given the following advice:
§ Keep skin clean and dry.
§ Use mild soaps—avoid scented and strong soaps.
§ Drink plenty of water to keep skin hydrated and in good health.
§ Avoid the sun when you have a rash.
§ Doctors may prescribe benadryl, or other antihistaminic medications to
relieve itching and rash.
§ If rash is severe, associated with peeling of skin, blistering, ulceration
or fever, contact the nurse or doctor immediately. You will need to change
the medication.
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(v) Neuropathynumbness and tingling
Numbness, tingling and burning of feet and hands is most commonly seen
with d4T, DDI, ddC, 3TC, Ritonavir. Other ARV medications and INH,
Rifampicin, can also cause neuropathy. Neuropathy with ARVs is usually
progressive unless the offending medication is changed. Patients should report
any symptoms to the nurse or physician. Neuropathy associated with INH or
other medications may be reversed. Medications need to be changed quickly
if associated with weakness and inability to walk. Symptoms can be relieved
with vitamin supplements, and antidepressants such as amitryptaline
prescribed by the physician.
The patient can be given the following advice:
§ Protect your feet.
§ Wear loose fitting shoes and socks.
§ Keep feet uncovered in bed.
§ Soak feet in warm water; massage feet.
§ Don’t walk too much at a stretch.
§ Ask doctor for pain relief medications, vitamin supplements.
§ If no improvement, or difficulty in walking, contact nurse or physician.
(vi) CNS symptoms
Bad dreams, nightmares, headache, insomnia, depression, anxiety, difficulty
in concentrating and dizziness are some symptoms seen with EFV. CNS
symptoms pass over time. Taking medication at bedtime helps alleviate some
of the symptoms. If symptoms do not improve or are associated with severe
depression, suicidal ideation and withdrawal, the patient must consult a nurse
or physician immediately. EFV may need to be replaced by another
medication.
The patient can be given the following advice:
§ Symptoms are usually temporary and pass in a few weeks.
§ Take EFV at bedtime to minimize effects.
§ Avoid a heavy meal before sleeping.
§ Avoid alcohol and drugs.
§ If you feel dizzy, sit down till the feeling goes away and try not to move
quickly or lift anything heavy.
§ Talk about your feelings with your friends or family.
§ If you feel very sad, or like crying all the time, or have thoughts of suicide,
contact the nurse or doctor.
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Fatigue is a fairly common complaint and has multiple causes. HIV infection
itself causes fatigue. Medications, depression, anemia can also cause fatigue. A
change in lifestyle, maintaining a regular routine, adequate rest, and a balanced
diet that includes vegetables and fruits, help to relieve fatigue. Patients should
be advised to not consume alcohol and not to use recreational drugs.
The patient can be given the following advice:
§ Avoid alcohol, tobacco and recreational drugs.
§ Light physical exercise helps.
§ Take a balanced diet that includes vegetables and fruits.
§ Consult a doctor if you feel depressed, sad of have thoughts of suicide.
(viii) Lipoatrophy, lipodystropy and changes in physical appearance
Patients who have been on treatment with d4T, or protease inhibitors, for
several months may notice changes in their physical appearance such as loss
of fat from their cheeks, temples and limbs with increased redistribution of
fat on the trunk. Lipoatrophy and lipodystrophy may be associated with
metabolic changes such as changes in lipid profile and blood sugar levels.
Patients should undergo routine check-ups by their physician. ARV
medications may need to be changed and new medications to manage these
side effects may be needed.
Hair loss is mostly seen with the use of Efavirenz. Hair loss is usually
temporary. Patients can be advised to protect the hair from damage by not
using hair-dyes and not braiding the hair. Patients should be discouraged
from using commercially advertised products, as these are not helpful.
(ix) Side effects requiring laboratory diagnosis.
Hepatitis, pancreatitis, anemia, renal dysfunction, lactic
acidosis, metabolic disturbances like hyperlipidemia or
hyperglycemia
These are side effects that are usually diagnosed through laboratory tests.
Non-specific symptoms such as nausea, vomiting, diarrhea or pain in the
abdomen may trigger the search for side effects such as lactic acidosis, pancre-
atitis, and hepatitis. For others such as hyperlipidemia or hyperglycemia,
routine follow-up laboratory monitoring may detect abnormal values.
These side effects or adverse drug reactions (ADRs) are to be managed by
the treating physician. Although nurse counselors may be able to identify
these reactions based on laboratory reports, the treating physician should
manage these events. Counselors should refer the patients to the physician at
the earliest.
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1. Inform the physician.






4. Medication will need to
be changed if lactic
acidosis, pancreatitis or
severe neuropathy occur.
Name Side effects Action to be taken
The table below contains information for providers on 6 antiretroviral
medications that are to be used in the ART program in Mombasa. These
antiretroviral medications include commonly used first and second line
medications recommended by WHO for use in developing country programs.
Additional detailed information on other drugs is available online on the US










1. Inform the physician.
2. Patients should report
severe abdominal pain, or
vomiting. If lactic acidosis,










1. Inform the physician.
2. Patients should report
severe abdominal pain,
vomiting.
3. Nausea and diarrhea




5. Medication will need to
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Rare: severe rash, liver
toxicity and hepatitis, severe
depression with suicidal
ideation
1. Inform the physician.
2. Mild-to-moderate rash
may disappear over 4
weeks.
EFV to be discontinued in
case of severe rash
(blistering, desquamation).
3. May consider changing
treatment in presence of
liver toxicity (enzymes
greater than 5 times
normal levels) or severe
rash.
4. Central nervous system
(CNS) symptoms generally
relieved when EFV is
taken at bedtime. In case
of severe CNS symptoms












1. Inform the physician.
2. Nausea and diarrhea
disappear over 2–4 weeks.
3. Patients should report
severe abdominal pain,
vomiting. Medication will
need to be changed if
lactic acidosis occurs.
Table contd.
Name Side effects Action to be taken
(Contd.)
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Rare: rash, liver toxicity,
hepatitis, lipodystrophy
1. Inform physician.
2. Liver enzymes in excess
of 5 times the normal
levels may require change
of medication.
3. Mild rash usually
disappears over time and
can be treated with
calamine lotion and anti-
histaminic medications.
















2. GI intolerance generally
disappears over time.
3. Hyperglycemia may
require insulin or oral
hypoglycemic agents.
4. Treatment may need to




6. Continue treatment in
cases with lipodystrophy.
7. Liver enzymes need
monitoring.
Table contd.
Name Side effects Action to be taken
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Glossary
Acute HIV Syndrome: Acute HIV syndrome is an acute ‘flu-like’ clinical syndrome
experienced by 50–70% individuals approximately 3–6 weeks after primary
infection. It is characterized by fever, pharyngitis, rash, body ache, joint pains
etc.
Confidentiality : The right to keep personal information, including medical
information, exclusive to oneself. In a health care service delivery site this
implies an assurance that personal and medical information is not disclosed to
unauthorized persons, processes or devices. Only the person concerned has the
right to disclose or sanction disclosure of personal information, except in
exceptional circumstances.
Dose response effect: Dose response effect refers to a casual relationship between
an exposure and an outcome or a disease. As the dose of exposure increases,
the risk of disease also increases. In the case of adherence to antiretroviral
therapy, as non-adherence to treatment increases, viral load levels increase in
the blood.
Encephalitis: Inflammation of the brain. It may be caused by a viral or bacterial
infection or may be part of an allergic response to a systemic viral illness or
vaccination.
Hepatitis: Inflammation of the liver. It may be caused by a viral, bacterial or amoebic
infection or may be part of an allergic response to medications. It can also
occur as an autoimmune condition.
Herpes zoster: An inflammation of the skin caused by a Varicella-zoster virus
(also causes chicken pox) characterized by collections of small blisters. Also
known as ‘shingles’.
Hyperglycemia: Raised levels of glucose in the blood typically seen in diabetes
mellitus. Hyperglycemia may be seen with the use of protease inhibitors.
Hyperlipidemia : Raised levels of one or more class of lipoproteins in the blood.
Lipids include cholesterol (LDL and HDL) and triglycerides. Use of Protease
Inhibitors and Stavudine may be associated with an increase in total cholesterol
and plasma triglycerides.
Hypersensitivity reactions: An allergic disorder in which the body becomes
hypersensitive to particular antigens, which provoke characteristic symptoms
whenever they are subsequently encountered.
Gold standard: An established and reliable standard against which a comparison
can be made.
Immune reactivation syndrome: A paradoxical worsening of pre-existing untreated
opportunistic infections seen following the initiation of effective antiretroviral
therapy. This reflects the immediate improvements in immune function that
occur as levels of HIV RNA drop and the immunosuppressive effects of HIV
infection are controlled. Immune reconstitution: restoration of the immune system.
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Immune suppression: Suppression of the immune system. This may be due to an
autoimmune illness, HIV infection or use of immunosuppressive medications.
Lactic acidosis: A condition resulting from an increase in serum lactate levels.
Most commonly seen with the class of nucleoside analog antiretroviral
medications such as Stavudine (d4T), Zidovudine (AZT), Lamivudine (3TC),
Abacavir etc.
Lipoatrophy : Loss of fatty tissue. Lipodystrophy : Any disturbance of fat
metabolism or of the distribution of fat in the body. In HIV/AIDS, lipodystrophy
involves the redistribution of fat from the face, extremities and buttocks to
around the abdomen resulting in peripheral wasting and truncal obesity. This is
most commonly seen with the use of Stavudine and protease inhibitors.
Lymphadenopathy: Enlargement of the lymph nodes. This may be due to an
infection or a malignant process.
Lymphoma: A tumour of the lymph nodes or lymphoid tissue.
Maximal and durable suppression of the virus: Near total and long-term
suppression of the virus to undetectable levels in the blood.
Meningitis: An inflammation of the meninges (connective tissue membranes that
line the skull and the vertebral canal) due to infection by viruses or bacteria.
Metabolic dysfunction: Metabolism involves the breakdown of complex organic
constituents of the body with liberation of energy, which is required for other
processes. In HIV/AIDS metabolic dysfunction with the use of antiretroviral
medications especially protease inhibitors relates to the disturbance of lipid
and glucose metabolism.
Mucocutaneous lesions: Lesions involving the mucous membranes and skin.
Neuropathy: Disease of the peripheral nerves, usually causing weakness and
numbness.
Opportunistic infections: Bacterial, viral or fungal infections that occur when the
immune system is suppressed.
Oral hairy cell leukoplakia: A mixed floral infection of the mucosal epithelium,
most often affecting the side of the tongue.
Oral thrush : Lesions in the oral cavity caused by a fungal infection (Candidiasis)
commonly seen in HIV/AIDS.
Pancreatitis: Inflammation of the pancreatic gland.
Protease inhibitors: A class of antiretroviral medications that inhibit HIV protease
enzyme. This class includes medications such as Ritonavir, Indinavir,
Amprenavir, Saquinavir, and Nelfinavir.
Recreational drugs: Addictive and narcotic drugs such as marijuana, cocaine,
opiates (heroin etc.).
Steven Johnson syndrome: Severe and serious allergic skin reaction with rash,
fever and blistering requiring hospitalization and immediate withdrawal of the
offending medication.
Suicidal ideation: Ideas or thoughts of committing suicide.
Toxoplasmosis: Disease of mammals due to a protozoan Toxoplasma gondii. In
HIV/AIDS can present as an encephalitis or space-occupying lesion in the brain.
Viral resistance: The degree to which the virus remains unaffected by antiretroviral
medications. This occurs when the virus is exposed to sub-optimal levels of
antiretroviral medications.
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